| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Alvotech$3.28
-0.04 (-1.2%)
C 51Pipeline Score Undervalued Biotech · Clinical
Market Cap
936.14 M
EPS
-0.26
P/E Ratio
-11.37 $
Value Trade
1.95 M
-2.05 %
Week
-5.38 %
1 Month
-20.67 %
3 Month
-34.77 %
6 Month
-65.8 %
5 Year
-65.74 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
397.73 K
52 Week Range
2.99 - 11.85
% held by Insiders
69.48 %
% held by Institutions
5.17 %
Enterprise Value
2.33 B
Total Shares
312.13 M
Short %
2.53 %
Float Shares
115.49 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alvotech
493Total events
10Upcoming
210Tier-1 (high impact)
2021 – 2028Coverage
Upcoming catalysts 10
Event history 483
Jul 1, 2026
Q2 2026
Q2 2026
▲Product LaunchAVT05ApprovedPost-Market
Launch of additional biosimilars in Japan in H1 2026
golimumab biosimilarsource ↗
Jun 25, 2026
▼Equity OfferingCorporate
Concurrent private placement of 17,826,666 shares at $3.75 to EEA investors, expected to close June 25, 2026
Jun 17, 2026
▼Equity OfferingCorporate
Priced and allocated 22,666,667 shares at $3.75 in US public offering, expected to close June 17, 2026
Jun 16, 2026
▼Equity OfferingCorporate
Pricing of $152 million public offering and concurrent private placement
Jun 15, 2026
▼Equity OfferingCorporate
Alvotech announces $125 million public offering of shares in the US and concurrent private placement to institutional investors in the EEA
Jun 8, 2026
Jun 8, 2026
▲BLA SubmissionAVT16Regulatory Filing
FDA accepted BLA for AVT16
ulcerative colitis, Crohn's diseasesource ↗
Jun 8, 2026
▲EMA ValidationAVT16Ex-US Regulatory
EMA validated MAA for AVT16 and AVT80
ulcerative colitis, Crohn's diseasesource ↗
Drug Pipeline Intelligence
C51
Pipeline Score $3.0B
Pipeline ValueUndervalued
Valuation Signal10
Drugs Scored3.2x
rNPV / MCap Top 78%
Micro Cap (rank 201 of 911)
Percentile RankAlvotech carries a moderate pipeline score (51/100), with $8.7B risk-adjusted pipeline value, led by Stelara in Psoriasis (Phase 3), across $89B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stelara Small molecule | Psoriasis | Phase 3 | NCT04930042 | 58% | $3.8B | COMPLETED | 581 | - | - | Oct 11, 2022 | - | Feb 2, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AVT80 | sáraristilbólgu og Crohns-sjúkdóm | — | 2026-02-05 | allar aðalendapunktar hennar uppfylltir | Alvotech kynnir jákvæða niðurstöðu rannsóknar á lyfjahvörfum AVT80, fyrirhugaðrar hliðstæðu við líftæknilyfið Entyvio Read More | |
AVT80 | sáraristilbólgu og Crohns-sjúkdóm | — | 2026-02-05 | allar aðalendapunktar hennar uppfylltir | Alvotech kynnir jákvæða niðurstöðu rannsóknar á lyfjahvörfum AVT80, fyrirhugaðrar hliðstæðu við líftæknilyfið Entyvio Read More | |
AVT80 | sáraristilbólgu og Crohns-sjúkdóm | — | 2026-02-05 | allar aðalendapunktar hennar uppfylltir | Alvotech kynnir jákvæða niðurstöðu rannsóknar á lyfjahvörfum AVT80, fyrirhugaðrar hliðstæðu við líftæknilyfið Entyvio Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALVO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALVO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ALVOAlvotech further strengthens liquidity by securing term loan facility of $75 million
Alvotech has secured a $75 million term loan facility led by GoldenTree Asset Management, enhancing its liquidity and financial position. This follows a recent $165 million equity raise, bringing total new capital access to $240 million. The funds will support Alvotech's R&D pipeline and global product launches, reflecting growing confidence in the company's strategy.
Read more →ALVOAlvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
Alvotech has successfully closed a public offering, raising approximately $165 million through the sale of ordinary shares. The offering included the full exercise of underwriters' options and a concurrent private placement. The funds will be utilized for the development of biosimilar assets and general corporate purposes. The offering was conducted under a previously filed registration statement with the SEC.
Read more →ALVO▼ -8.7%on this newsshared move
Alvotech tilkynnir um verð og úthlutun hlutabréfa að andvirði um 152 milljónir dollara í útboði í Bandaríkjunum og lokuðu útboði til fagfjárfesta á Evrópska efnahagssvæðinu
Alvotech announced a public offering in the U.S. to raise approximately $152 million by issuing 22.67 million shares at $3.75 each. The offering is set to close on June 17, 2026, and includes an option for underwriters to purchase additional shares. The funds will support the development of new biosimilars and cover operational costs.
Read more →ALVO▼ -8.7%on this newsshared move
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
Alvotech has announced the pricing of a public offering of 22,666,667 ordinary shares at $3.75 each, aiming to raise approximately $152 million. The offering is set to close on June 17, 2026, and includes a concurrent private placement of 17,826,666 shares. Proceeds will be used for the development of biosimilar products and general corporate purposes.
Read more →ALVO▼ -8.7%on this newsshared move
Alvotech efnir til útboðs á hlutabréfum í Bandaríkjunum að andvirði 125 milljónir dollara samhliða lokuðu útboði til fagfjárfesta á Evrópska efnahagssvæðinu
Alvotech has announced a public offering in the U.S. aimed at raising approximately $125 million. The company will allow underwriters to purchase up to 15% of the offered shares within 30 days. Proceeds from the offering are intended to finance the development of new biosimilar medications and cover operational costs. The offering is structured under SEC regulations.
Read more →ALVO▼ -8.7%on this newsshared move
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
Alvotech has announced a proposed public offering of $125 million in ordinary shares, along with a concurrent private placement. The proceeds will be used to support the development of biosimilar assets and general corporate purposes. The offering is subject to market conditions, and the allocation of shares between the public offering and private placement is yet to be determined.
Read more →ALVO▲ +19.8%on this news
Matvæla- og lyfjastofnun Bandaríkjanna tekur til afgreiðslu umsókn Alvotech um markaðsleyfi fyrir AVT16, fyrirhugaða hliðstæðu við Entyvio
Alvotech announced that the FDA has accepted its application for market approval of AVT16, a proposed biosimilar to Entyvio (vedolizumab). This marks a significant step in Alvotech's efforts to enhance patient access to critical therapies. The collaboration with Teva Pharmaceutical will support the development and commercialization of AVT16 in the U.S.
Read more →ALVO▲ +19.8%on this news
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
Alvotech announced the FDA's acceptance of its Biologics License Application for AVT16, an interchangeable biosimilar to Entyvio. This development is part of Alvotech's strategy to enhance access to biosimilar medicines. The application is backed by extensive data demonstrating biosimilarity, and if approved, AVT16 will provide more treatment options for patients.
Read more →ALVO▲ +19.1%on this news· ran to +32% by day 3shared move
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi and Simponi Aria , and AVT06, a proposed biosimilar to Eylea
Alvotech has announced the resubmission of Biologics License Applications for AVT05, a biosimilar to Simponi, and AVT06, a biosimilar to Eylea, to the FDA. This follows responses to FDA feedback regarding the company’s manufacturing facility in Reykjavik. The resubmissions represent a significant milestone as Alvotech continues to strengthen its quality systems and processes. The FDA is expected to conduct a review within six months, in line with standard regulatory timelines.
Read more →ALVOAlvotech to present at upcoming investor conferences in June 2026
Alvotech has announced that its Founder and Executive Chairman, Robert Wessman, along with Chief Strategy Officer Dr. Balaji V. Prasad, will present at investor conferences in June 2026. The events will be accessible via live audio webcasts, with recordings available for 90 days post-event. Alvotech continues to strengthen its position in the biosimilar market with a diverse pipeline.
Read more →ALVONiðurstaða aðalfundar Alvotech árið 2026
Alvotech has scheduled its annual general meeting for June 3, 2026, in Luxembourg. All proposals on the agenda were unanimously approved during the meeting. Detailed minutes and voting results will be made available on the company's investor relations website.
Read more →ALVO▼ -6.8%on this newsshared move
Alvotech tekur þátt í þremur fjárfestaráðstefnum í Bandaríkjunum í júní
Alvotech will participate in three investment conferences in the U.S. in June 2026. Key executives will present the company to investors and answer questions from analysts. The conferences include events hosted by Jefferies, Goldman Sachs, and UBS, with live streaming available for attendees.
Read more →ALVO▼ -6.8%on this newsshared move
Alvotech to present at upcoming investor conferences in June
Alvotech has announced its participation in several investor conferences in June 2026, including the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference. Key executives, Robert Wessman and Dr. Balaji V. Prasad, will engage in fireside chats to discuss the company's developments. Live webcasts will be accessible to the public, with recordings available post-event.
Read more →ALVOAlvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
Alvotech has renewed its market-making agreement with Islandsbanki to enhance trading of ALVO shares on Nasdaq Iceland. The agreement stipulates that Islandsbanki will maintain a minimum market value of ISK 8 million in bid and ask quotes. The maximum spread between quotes is set at 2.5%, with a daily trading limit of ISK 16 million. The agreement has no fixed term and can be terminated with a 7-day notice.
Read more →ALVOAlvotech og Íslandsbanki endurnýja samning um viðskiptavakt með bréf félagsins í Kauphöllinni
Alvotech has renewed its market-making agreement with Íslandsbanki to enhance trading of its shares listed on Nasdaq Iceland. The agreement includes provisions for active buy and sell offers, aimed at increasing liquidity and establishing a fair market price for Alvotech's stock. The contract is effective until May 29, 2026, and can be terminated with a seven-day notice.
Read more →ALVO▲ +10.1%on this news
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility
Alvotech has successfully completed a routine FDA cGMP surveillance inspection at its Reykjavik facility, receiving a Form 483 with observations that the company believes can be quickly addressed. This positions Alvotech to resubmit its Biologics License Applications within the quarter. The company remains optimistic about receiving FDA approval for these applications in 2026.
Read more →ALVO▲ +10.1%on this newsshared move
Matvæla- og lyfjaeftirlit Bandaríkjanna lýkur úttekt á framleiðsluaðstöðu Alvotech
The FDA has completed a routine inspection of Alvotech's manufacturing facility in Reykjavik, providing feedback that the company plans to address promptly. Alvotech is now positioned to submit new market authorization applications for its products. The inspection confirmed that the facility complies with stringent cGMP requirements, and the company anticipates FDA approval within the year.
Read more →ALVO▲ +10.1%on this newsshared move
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
Alvotech has successfully completed a routine FDA surveillance inspection at its Reykjavik facility, receiving a Form 483 with no substantial issues noted. The company plans to resubmit its Biologics License Applications in the second quarter of 2026, bolstered by the inspection's positive outcome. Alvotech continues to anticipate FDA approval for its relevant BLAs within the year.
Read more →ALVOAlvotech birtir uppgjör fyrsta ársfjórðungs 2026
Alvotech (NASDAQ: ALVO) released its financial results for Q1 2026, reporting total revenues of $105.9 million, a decline from the previous year's $132.8 million. The company is actively pursuing market approvals for its biosimilars AVT16 and AVT80 in Europe and has commenced clinical trials for AVT29. Alvotech has also partnered with FUJIFILM Biotechnologies to enhance its manufacturing capabilities. Despite the revenue decline, there is a noted strong demand for its products in the market.
Read more →ALVOAlvotech Q1 2026 Financial Results
Alvotech reported Q1 2026 revenues of $105.9 million, down from $132.8 million year-over-year. The company submitted a Marketing Authorization Application for its biosimilars and commenced pivotal studies for new products. Despite a production slowdown affecting revenues, management expects a recovery and projects total revenues between $650-$700 million for 2026.
Read more →ALVOAlvotech tilkynnir breytingu í framkvæmdastjórn
Alvotech announced that Tanya Zharov, the company's legal executive, has decided to step down after six years. Robert Wessman, the chairman, expressed gratitude for her contributions, highlighting her role in the company's international expansion. Zharov will continue to support the company during the transition and will remain involved with associated firms.
Read more →ALVOAlvotech Announces a Change in its Executive Team
Alvotech announced the resignation of Tanya Zharov, General Counsel, after six years. She played a key role in the company's growth and public listings. Lisa Graver will succeed her as CEO, while Zharov will assist during the transition period. Alvotech continues to focus on developing biosimilar medicines.
Read more →ALVOAlvotech birtir uppgjör fyrsta ársfjórðungs 2026 þann 6. maí nk.
Alvotech (NASDAQ: ALVO) will publish its first quarter earnings report for 2026 on May 6, following market closure in the U.S. A live-streamed presentation will take place on May 7 at noon. Interested participants can register for the stream and submit questions to management.
Read more →ALVOAlvotech to Report Financial Results for the First Quarter of 2026
Alvotech will announce its first quarter 2026 financial results on May 6, 2026, after market close. A live Q&A webcast is scheduled for May 7, 2026. The company focuses on biosimilar medicines and has a robust pipeline, including five approved products and nine candidates in development.
Read more →ALVO▲ +5.8%on this news· ran to +17% by day 3
Alvotech birtir ársreikning á eyðublaði 20-F
Alvotech has announced the publication of its 2025 financial report on Form 20-F, complying with SEC regulations. The report is available on the SEC website and Alvotech's investor relations page. Alvotech specializes in the development and manufacturing of biosimilars, targeting various medical conditions. The company has established partnerships for marketing and distribution across major global markets.
Read more →ALVO▲ +5.8%on this news· ran to +17% by day 3
Alvotech Files Annual Report with the SEC
Alvotech has submitted its Annual Report for 2025 to the SEC, highlighting its commitment to transparency and regulatory compliance. The report includes details about its financial performance and ongoing projects. The company continues to focus on the development of biosimilars, with five already approved and a pipeline of nine candidates targeting various medical conditions.
Read more →ALVO▲ +5.8%on this news· ran to +17% by day 3
Alvotech birtir ársskýrslu fyrir árið 2025
Alvotech has announced that it will release its annual report for the year 2025. The report will be available on their investor website and will follow the iXBRL standard. Alvotech is dedicated to the development and manufacturing of biopharmaceuticals, targeting various medical conditions.
Read more →ALVO▲ +5.8%on this news· ran to +17% by day 3
Alvotech Publishes 2025 Annual Report
Alvotech has released its Annual Report for 2025, detailing its ongoing commitment to developing biosimilar medicines. The report highlights the company's achievements, including five approved biosimilars and a robust pipeline of nine candidates targeting various diseases. The report is accessible on their investor relations website.
Read more →ALVO▼ -5.8%on this news· ran to -18% by day 3
Alvotech Q4 2025 and Full Year 2025 Financial Results
Alvotech reported solid financial results for Q4 and the full year of 2025, highlighting a 21% YoY increase in total revenues to $593 million. The company achieved key approvals for multiple biosimilar products, significantly expanding its market presence. However, it is working to resolve regulatory feedback from the FDA related to its manufacturing practices. Looking ahead, Alvotech anticipates substantial revenue growth in 2026 while addressing these regulatory challenges.
Read more →ALVOAlvotech birtir uppgjör ársins 2025 og fjórða ársfjórðungs
Alvotech reported strong financial results for the fourth quarter of 2025, with total revenues reaching $173 million, a 13% increase year-over-year. The company also achieved significant EBITDA growth and received market approvals for several biosimilars in Europe. Looking ahead, Alvotech anticipates total revenues of $650-700 million for 2026, driven by new product launches and market expansions.
Read more →ALVOAlvotech to Report Fourth Quarter and Full Year 2025 Financial Results
Alvotech will announce its fourth quarter and full year 2025 financial results on March 18, 2026. A conference call with a live Q&A session is scheduled for March 19, 2026. The company specializes in biosimilar medicines and has several products approved in multiple markets, with a strong pipeline of candidates in development.
Read more →ALVOAlvotech kynnir uppgjör ársins 2025 þann 19. mars nk.
Alvotech (NASDAQ: ALVO) will release its 2025 financial results on March 18, 2026, after market close. A presentation will follow on March 19, 2026, at noon, available via live stream. The company specializes in developing biosimilars and has established partnerships for marketing and distribution globally.
Read more →ALVOAlvotech Announces Increase in Number of Own Shares
Alvotech has announced an increase in its share capital by issuing 12.5 million ordinary shares at USD 5.2 each, totaling USD 125,000. The subsidiary, Alvotech Manco ehf., will hold these shares as treasury shares without voting rights. This capital increase aims to maintain sufficient shares for financial commitments, including employee compensation and convertible instruments.
Read more →ALVOAlvotech tilkynnir um aukningu í fjölda eigin bréfa
Alvotech has announced the issuance of 12.5 million new shares, which will be purchased by its subsidiary, Alvotech Manco ehf, at a price of $5.20 per share. This increase in share capital will enhance Alvotech's ability to meet financial obligations, including employee incentive programs. Following this transaction, the total number of shares outstanding will rise to 346,538,147.
Read more →ALVOAlvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
Alvotech announced positive top-line results from a pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio. The study demonstrated pharmacokinetic similarity and met all primary endpoints, paving the way for regulatory submissions. This milestone highlights Alvotech's strong development capabilities in the biosimilar space.
Read more →ALVOAlvotech kynnir jákvæða niðurstöðu rannsóknar á lyfjahvörfum AVT80, fyrirhugaðrar hliðstæðu við líftæknilyfið Entyvio
Alvotech announced positive results from its AVT80 biosimilar study, comparing it with Entyvio (vedolizumab). The study met all primary endpoints, indicating similar pharmacokinetics, safety, and tolerability. This achievement marks a significant milestone for Alvotech as it prepares to initiate market authorization applications. The results underscore the company's strength in biosimilar development.
Read more →ALVOAlvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
Alvotech has signed supply and commercialization agreements with Sandoz for multiple biosimilar candidates in Canada, Australia, and New Zealand. These agreements are designed to facilitate patient access to biosimilars following regulatory approvals. Sandoz will handle regulatory submissions and commercialization, while Alvotech will focus on development and manufacturing.
Read more →ALVOAlvotech gerir samninga um markaðssetningu á fyrirhuguðum hliðstæðum í Kanada, Ástralíu og Nýja-Sjálandi
Alvotech has announced agreements with Sandoz for the sale and marketing of biosimilars in Canada, Australia, and New Zealand. These agreements are intended to ensure access to key markets for new biosimilars. Alvotech will focus on the development and manufacturing of these products, while Sandoz will handle marketing and sales. This collaboration aims to improve patient access to affordable biosimilars.
Read more →ALVOAlvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
Alvotech has reached a settlement agreement with Regeneron and Bayer, resolving all patent disputes related to its biosimilar to Eylea. This agreement allows Alvotech to market the biosimilar in the UK, Canada, and Japan, with a global launch planned for early 2026. The company is well-positioned for a successful entry into these markets, supported by strong commercial partnerships.
Read more →ALVOAlvotech nær samningum um alþjóðlega markaðssetningu hliðstæðu við augnlyfið Eylea
Alvotech has finalized a licensing agreement with Regeneron and Bayer for the marketing of its biosimilar to Eylea, allowing it to enter markets in the UK, Canada, Japan, and Europe. The agreement resolves previous intellectual property disputes and enables Alvotech to market the product starting January 1 in certain regions. This strategic move is expected to strengthen Alvotech's position in the global healthcare market.
Read more →ALVO▼ -6.5%on this news
Alvotech announces planned CEO succession and leadership transition
Alvotech has announced a planned leadership transition, appointing Lisa Graver as the new Chief Executive Officer, succeeding founder Róbert Wessman, who will remain as Executive Chairman. The transition reflects a strategic decision to strengthen the company's leadership while maintaining its base in Iceland. Wessman emphasizes the importance of having leadership aligned with the company's operations and expresses confidence in Graver's capabilities and experience. This leadership change occurs as Alvotech continues to expand its pipeline of biosimilar medicines.
Read more →ALVOAlvotech Secures Term Loan Facility of USD 100 Million
Alvotech has announced a $100 million senior term loan facility with a maturity in December 2027 to enhance liquidity and support its strategic initiatives for 2026. This financing, led by GoldenTree Asset Management, reflects confidence in Alvotech's growth potential and its robust biosimilar product pipeline, which includes 30 products in development. The company aims to strengthen its R&D efforts and expand production capacity for upcoming global product launches.
Read more →ALVOAlvotech og Advanz Pharma hefja sölu í Evrópu á fyrstu hliðstæðunni við Simponi
Alvotech has announced the launch of Gobivaz, a biosimilar to Simponi, in Europe. This marks the first biosimilar of Simponi available globally. Advanz Pharma will exclusively market Gobivaz in Europe, with NHS England committing to purchase it to enhance access for patients with chronic inflammatory conditions. The approval was based on comprehensive clinical studies demonstrating its equivalence to the original drug.
Read more →ALVOAlvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
Alvotech has launched Gobivaz, the first biosimilar to Simponi, in Europe through Advanz Pharma. Supported by an NHS England tender, Gobivaz aims to improve access to biologic treatments for inflammatory diseases. The product is manufactured in Iceland and has undergone extensive studies to ensure biosimilarity to the reference product.
Read more →ALVOAlvotech’s Financial Calendar for 2026
Alvotech has announced its financial calendar for 2026, detailing key dates for quarterly and annual results. Following each earnings release, an investor call will be conducted to discuss the results. The schedule includes specific dates for Q1, Q2, and Q3 results, as well as the full-year report for 2026. All dates are subject to change, highlighting the company's commitment to transparency and investor engagement.
Read more →ALVOAlvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
Alvotech and Teva Pharmaceuticals have secured a settlement and license agreement with Regeneron for the launch of AVT06, a proposed biosimilar to Eylea. The agreement allows for a U.S. market entry date in the fourth quarter of 2026, contingent on FDA approval. AVT06 has already received marketing approvals in Europe and Japan, and recent clinical studies show promising results.
Read more →ALVOAlvotech og Teva ná samningi um að sala AVT06 hliðstæðunnar við Eylea má hefjast í Bandaríkjunum á fjórða ársfjórðungi 2026
Alvotech and Teva Pharmaceuticals have entered into an agreement with Regeneron to market AVT06, a biosimilar to Eylea, in the U.S. Sales could commence in Q4 2026, contingent upon meeting specific conditions. Alvotech has already received marketing approvals for AVT06 in Japan, the UK, and across Europe. Recent clinical trials demonstrated comparable efficacy and safety between AVT06 and Eylea.
Read more →ALVOMikil umframeftirspurn alþjóðlegra fjárfesta í útboði Alvotech á breytanlegra skuldabréfum að fjárhæð 108 milljónir dollara
Alvotech announced the successful sale of convertible bonds totaling $108 million, driven by high investor demand. This funding will aid in the development of new biosimilar therapies, with plans to introduce 30 new products in the coming years. The company aims to enhance its manufacturing and marketing capabilities globally.
Read more →ALVOAlvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
Alvotech has successfully placed USD 108 million in senior unsecured convertible bonds due 2030 in an offering that was significantly oversubscribed. The proceeds will support the company's ongoing research and development efforts, projected at around USD 250 million for 2026, and will facilitate the scaling up of production capacity for upcoming global product launches. This bond placement reflects strong investor faith in Alvotech's business model and pipeline of biosimilar products.
Read more →ALVO▼ -6.7%on this newsshared move
Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance
Alvotech has announced the launch of a $100 million senior unsecured convertible bond offering to support its ongoing investment in research and development, scaling manufacturing, and preparing for global product launches. The company reaffirms its financial outlook for 2025 while providing guidance for 2026, which considers possible FDA approval delays. Alvotech aims to launch 4 new products in 2026 and is optimistic about receiving necessary approvals for its biosimilar products in the U.S. Despite potential challenges, the outlook remains positive with significant revenue expectations.
Read more →ALVO▲ +6.4%on this news
Markaðsleyfi veitt á Evrópska efnahagssvæðinu fyrir AVT03, hliðstæðu Alvotech við líftæknilyfin Prolia og Xgeva
Alvotech has announced that the European Commission granted marketing authorization for AVT03, a biosimilar to Prolia and Xgeva, which contain denosumab. This approval is expected to enhance patient access to treatments for bone loss and cancer-related bone conditions. The company plans to market AVT03 in collaboration with partners STADA and Dr. Reddy's across Europe.
Read more →ALVO▲ +6.4%on this news
Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area
Alvotech has received European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, aimed at treating osteoporosis and preventing skeletal-related events in cancer patients. This approval highlights Alvotech's commitment to providing affordable biosimilars and improving access to essential treatments in Europe. The product will be marketed in partnership with STADA and Dr. Reddy's, enhancing its distribution across the region.
Read more →ALVO▲ +6.4%on this newsshared move
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Alvotech (ALVO) is under scrutiny from Hagens Berman due to concerns over its disclosures related to its lead drug candidate and manufacturing operations. Following an FDA issuance of a Complete Response Letter indicating deficiencies in its Reykjavik facility, Alvotech's revenue projections for 2025 have been severely cut. The lowered forecasts have prompted a dramatic drop in share value, with the stock tumbling by about 33%. The investigation focuses on whether Alvotech misled investors regarding its FDA interactions and the prospects of its product AVT05.
Read more →ALVOAlvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
Alvotech and Advanz Pharma have received marketing approval from the European Commission for Gobivaz®, a biosimilar to Simponi® (golimumab). This approval covers various formulations for treating immune-mediated diseases in adults and children. The decision follows a positive opinion from the EMA and highlights the companies' commitment to expanding access to biologic medicines in Europe.
Read more →ALVOAlvotech og Advanz Pharma fá markaðsleyfi á Evrópska efnahagssvæðinu fyrir Gobivaz, fyrstu hliðstæðuna við Simponi
Alvotech has announced that its biosimilar Gobivaz, a treatment for chronic inflammatory diseases, has received market authorization in the European Economic Area. This authorization, granted by the European Commission, follows positive recommendations from the European Medicines Agency. The collaboration with Advanz Pharma aims to enhance access to affordable treatment options across Europe.
Read more →ALVOAlvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
Alvotech reported strong financial results for the first nine months of 2025, highlighting significant revenue growth driven by new biosimilar launches. The company remains optimistic about future product introductions and has appointed a new COO to enhance operations. Despite challenges from an FDA inspection, Alvotech's facility remains approved, and production continues for various markets.
Read more →ALVOAlvotech kynnir uppgjör fyrstu níu mánaða ársins 2025 og helstu áfanga í rekstri félagsins
Alvotech (NASDAQ: ALVO) has announced its financial results for the first nine months of 2025, highlighting significant revenue growth driven by the sales of its biosimilars AVT02 and AVT04. The company is preparing for upcoming product launches in Europe and Japan. Despite a decline in licensing revenues, Alvotech remains optimistic about its future prospects and market positioning.
Read more →ALVOUK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
Alvotech has secured a favorable ruling from the UK High Court, allowing it to manufacture and market its biosimilar AVT06, which is similar to Eylea. The court rejected an injunction request from Regeneron and Bayer, facilitating Alvotech's commercial launch in the UK and European Economic Area. This decision is expected to enhance patient access to biologics.
Read more →ALVOAlvotech vinnur sigur í mikilvægu dómsmáli um framleiðslu og markaðssetningu AVT06 hliðstæðunnar við Eylea (aflibercept)
Alvotech has announced a favorable ruling from a UK court, rejecting a injunction request from Regeneron Pharmaceuticals and Bayer. This ruling permits Alvotech to market its biosimilar AVT06, related to the drug Eylea, in the UK and Europe. The decision is expected to facilitate quicker access to the drug for patients following the expiration of Eylea's patent protection.
Read more →ALVO▲ +12.8%on this newsshared move
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
Alvotech is under investigation by Bragar Eagel & Squire, P.C. on behalf of stockholders due to potential violations of federal securities laws. The investigation follows the receipt of a Complete Response Letter from the FDA regarding Alvotech's AVT05 BLA biologics license application, triggered by a failed facility inspection. Consequently, Alvotech's stock experienced a significant decline of 34.25%, closing at $5.03 per share.
Read more →ALVOAlvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
Alvotech and Advanz Pharma have received marketing authorizations from the UK MHRA for Gobivaz®, a biosimilar to Simponi® (golimumab). This approval allows for the treatment of various immune-mediated diseases, including rheumatoid arthritis and ulcerative colitis. The partnership aims to improve patient access to this important biologic therapy across the UK.
Read more →ALVOAlvotech INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (ALVO)
Alvotech is under investigation by Kirby McInerney LLP for potential claims related to violations of federal securities laws and unlawful business practices. The investigation follows the FDA's issuance of a complete response letter for Alvotech's biologics license application for AVT05, which was prompted by a failed facility inspection in July 2025. As a result of this negative news, Alvotech's stock price declined dramatically by over 34%, reflecting investor concerns about the company's future compliance and market viability.
Read more →ALVOAlvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekstri félagsins þann 13. nóvember nk.
Alvotech (NASDAQ: ALVO) will announce its Q3 2025 earnings on November 12, 2025, after market close. A presentation will be streamed live on November 13, where management will discuss the company's performance and market authorization applications in the U.S. and Europe. The company specializes in the development of biosimilars.
Read more →ALVOAlvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update
Alvotech has announced a webcast scheduled for November 13, 2025, to present its financial results for the first nine months of the year and provide a business update. The announcement was made in conjunction with the release of the financial results, expected after U.S. markets close on November 12, 2025. During the conference call, management will discuss pending approvals in the U.S. and Europe. Alvotech aims to become a leader in the biosimilar sector and currently has two approved biosimilars and nine additional candidates in development.
Read more →ALVO▼ -34.2%on this newsshared move
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
Alvotech announced that the FDA issued a Complete Response Letter for its Biologics License Application for AVT05, a biosimilar to Simponi. The CRL cited certain deficiencies found during a recent pre-license inspection of its Reykjavik manufacturing facility. Despite this setback, the company remains FDA approved for current production and has submitted a Corrective and Preventive Action plan to address the issues. Following the CRL, Alvotech has revised its 2025 revenue and adjusted EBITDA expectations downwards due to ongoing investments in resolving the facility issues.
Read more →ALVOAlvotech Announces Changes in Global Business Development and Commercial Operations Team
Alvotech has announced significant changes to its global business development and commercial operations team. Anil Okay will step down as Chief Commercial Officer to become CEO of Adalvo, while Trisha Durant joins as Senior Vice President for Global Business Development and Commercial Operations, ex-North America. Harshika Sarbajna and Agne Pasko will also play crucial roles in managing North American partnerships and global business development, respectively. This restructuring aims to enhance Alvotech's commercial strategy and operational success.
Read more →ALVOAlvotech Announces Marketing Approval in Japan of Three New Biosimilars
Alvotech has announced that its partner, Fuji Pharma, received marketing approval from Japan's Ministry of Health for three new biosimilars: AVT03 (denosumab), AVT05 (golimumab), and AVT06 (aflibercept). AVT05 marks a significant milestone as the first golimumab biosimilar approved in major global markets. These approvals aim to enhance patient access to biologic medicines and address the growing demand for cost-effective treatment options for chronic diseases. The company continues to expand its presence in Japan, having previously launched a biosimilar to Stelara in May 2024.
Read more →ALVOAlvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
Alvotech (NASDAQ: ALVO), a biotech firm focused on biosimilars, will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York from September 8-10, 2025. On September 9, the company will engage with investors, and on September 10, Dr. Balaji Prasad will take part in a fireside chat. The event will feature a live webcast, making it accessible to the general public, with a replay available for 90 days afterward. Alvotech continues to grow its presence in the biopharma sector with a focus on innovative biosimilar solutions.
Read more →ALVO▼ -5.4%on this news
Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia
Alvotech has appointed Patrik Ling as the new VP of Investor Relations for Scandinavia, based in Stockholm. With over 25 years of experience in the life sciences sector, including a recent role as Senior Equity Analyst, Ling is expected to bolster the company's engagement with Scandinavian investors. The appointment is timely as Alvotech expands its portfolio and R&D operations in Sweden, aiming to solidify its position as a leader in the biosimilar market. CEO Róbert Wessman expressed confidence in Ling's ability to enhance understanding of the company’s strengths among investors.
Read more →ALVOAlvotech Reports Results for the First Six Months of 2025 and Provides a Business Update
Alvotech has reported a significant performance boost in the first half of 2025, showcasing over 200% growth in product revenues and achieving its best quarterly operating cash flow. Strategic partnerships are expanding in the biosimilar market, which includes new agreements with Advanz Pharma and Dr. Reddy's Laboratories. However, the company noted a decrease in license and other revenue, as well as rising general and administrative costs. Overall, Alvotech maintains a strong cash position and continues to invest in developing its pipeline.
Read more →ALVOAlvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT
Alvotech, a biotech company specializing in biosimilars, has announced that it will report its financial results for the first half of 2025 on August 13, 2025. A conference call to discuss the results and provide recent business highlights is scheduled for August 14, 2025, at 8:00 am EDT. The event will be accessible via a live webcast, with an archived replay available for 90 days following the event. Alvotech currently has approved biosimilars on the market and a development pipeline that includes candidates targeting various health conditions.
Read more →ALVOExecution Version AMENDMENT NO. 2 TO TERM LOAN CREDIT AGREEMENT This AMENDMENT NO. 2 TO TERM LOAN CREDIT AGREEMENT, dated as of
Alvotech has announced Amendment No. 2 to its Term Loan Credit Agreement, which includes a reduction in the applicable interest rates and the establishment of a new tranche of Incremental Term Loans totaling $169 million. This amendment is intended to facilitate refinancing of existing loans and enhance the company's financial position. The changes also involve waivers related to prepayments and other financial arrangements in line with the updated agreement.
Read more →ALVOAlvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland
Alvotech has announced the acquisition of Ivers-Lee Group to expand its assembly and packaging capacity. Ivers-Lee will remain a separate entity but will integrate into Alvotech’s Technical Operations division, enhancing flexibility and capacity for future growth. The acquisition will support Alvotech’s plans for launching three new biosimilars in 2025, indicating a strategic move to address increasing global demand. This collaboration aims to maintain high standards in service and quality.
Read more →ALVOAlvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia (certolizumab pegol)
Alvotech and Advanz Pharma have announced a supply and commercialization agreement for AVT10, a biosimilar candidate to Cimzia (certolizumab pegol), marking a significant step in their strategic partnership. This agreement emphasizes the focus on expanding access to biologics in Europe, targeting chronic rheumatic diseases. The collaboration aims to leverage Alvotech's biosimilar development expertise, with an expected market launch of the product planned for Q4 2025. Certolizumab pegol has reported global sales of $2.3 billion in 2024, highlighting the competitive potential of this new biosimilar in the market.
Read more →ALVOAlvotech’s Lenders Lower Interest on Senior Secured Term Loan Facility
Alvotech has successfully negotiated a reduction in the interest rate on its senior secured term loan facility, leading to projected savings of US$8.2 million over the first year. This outcome is attributed to the company's strong operational performance, which includes revenue growth and positive EBITDA. The loan, structured as a single tranche with an interest rate of SOFR plus 6.0%, simplifies the company's capital structure and demonstrates lender confidence in Alvotech's growth prospects and pipeline advancements. As of June 25, 2025, the total balance of the Facility stands at approximately $1,081 million.
Read more →ALVOAlvotech’s Private Placement Completed with Delivery of SDRs and Shares to Investors
Alvotech has successfully completed a private placement aimed at Swedish and international institutional investors, attracting about 40 investors, with a significant portion coming from Sweden, Norway, and the UK. The placement has diversified Alvotech's shareholder base and enhanced the liquidity of its shares on Nasdaq Stockholm, with over 80% allocated to new investors. A total of 7.5 million treasury shares have been delivered to the participating investors, marking a significant milestone for the company as it continues its focus on the biosimilars market.
Read more →ALVOAlvotech Participates in the Goldman Sachs Global Healthcare Conference in Miami
Alvotech (NASDAQ: ALVO) announced its participation in the Goldman Sachs 46th Global Healthcare Conference, scheduled for June 9-11, 2025, in Miami, Florida. The company's management team will host one-on-one meetings, and Dr. Balaji Prasad will participate in a fireside chat on June 11, 2025. A live webcast of the chat will be available to the public, with a recording accessible for 90 days afterwards. Alvotech focuses on developing biosimilar medicines and has a pipeline targeting various medical conditions.
Read more →ALVOAlvotech Meets Investors and Presents at the Goldman Sachs Global Healthcare Conference in Miami
Alvotech (NASDAQ: ALVO) announced its participation in the Goldman Sachs 46th Global Healthcare Conference, scheduled for June 9-11, 2025, in Miami, Florida. Key management members, including Dr. Balaji Prasad, will host one-on-one meetings and participate in a fireside chat. The company is dedicated to the development and manufacture of biosimilar medicines, aiming to lead in this market with a broad pipeline targeting various diseases. A live webcast of the fireside chat will be available, with a recording accessible post-event for 90 days.
Read more →ALVOAlvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab)
Alvotech and Dr. Reddy’s Laboratories have announced a collaboration to co-develop a biosimilar candidate to Keytruda (pembrolizumab) for global markets. This partnership is aimed at leveraging the strengths of both companies to accelerate the development and commercialization of the biosimilar, which is notable due to Keytruda's significant sales of $29.5 billion in 2024. The agreement outlines shared responsibilities for development and manufacturing, emphasizing the commitment of both companies to enhance access to affordable cancer treatments worldwide.
Read more →ALVOAlvotech has carried out a private placement of 7,500,000 SDRs and ordinary shares at a price of SEK 100.00 per SDR and ISK 1320.83 per ordinary share, raising gross proceeds of SEK 750 million
Alvotech has completed a private placement of 7,500,000 shares, raising gross proceeds of SEK 750 million. The shares were sold at SEK 100.00 for each Swedish Depository Receipt (SDR) and ISK 1320.83 for ordinary shares. The placement attracted significant interest from institutional investors, mainly outside of Iceland. The funds will be directed towards enhancing R&D efforts, capitalizing on growth opportunities, and other general corporate purposes.
Read more →ALVO▼ -5.4%on this newsshared move
Alvotech intends to carry out a private placement of approximately 7.5 million SDRs and ordinary shares
Alvotech has announced its intention to conduct a private placement of approximately 7.5 million Swedish Depository Receipts (SDRs) and ordinary shares aimed at institutional investors. The placement will utilize existing treasury shares and is set to commence immediately under an accelerated bookbuilding procedure. Expected proceeds will support the acceleration of the company's R&D efforts following its recent acquisition of Xbrane's R&D operations. The company's Board believes this move will strengthen its shareholder base, especially in Sweden.
Read more →ALVO▼ -5.4%on this newsshared move
Alvotech Completes Acquisition of Xbrane R&D Organization and biosimilar candidate to Cimzia
Alvotech has completed its acquisition of the R&D organization of Xbrane Biopharma AB, as well as a biosimilar candidate for Cimzia. The transaction, valued at approximately SEK 275 million, fulfills all regulatory conditions. This strategic move is expected to enhance Alvotech's development capabilities and solidify its presence in Sweden's life sciences sector. Alvotech continues to focus on producing high-quality biosimilars and expanding its product pipeline for various therapeutic areas.
Read more →ALVOAlvotech Meets Investors and Presents at the Jefferies Global Healthcare Conference 2025 in New York, NY
Alvotech (NASDAQ: ALVO) announced its participation in the Jefferies Global Healthcare Conference 2025 in New York, scheduled for June 3-5, 2025. Dr. Balaji Prasad, the Chief Strategy Officer, will present recent business updates during a dedicated session. The company emphasizes its role in the biosimilars market, aiming to establish itself as a leader through strategic partnerships and a diverse development pipeline. A live video webcast of the presentation will be available, followed by a 90-day replay option.
Read more →ALVOAlvotech and Advanz Pharma Extend Strategic Partnership to Commercialize Three Additional Biosimilars in Europe
Alvotech has expanded its strategic partnership with Advanz Pharma to commercialize three additional biosimilar candidates in Europe, including products targeting Ilaris® and Kesimpta®. This agreement will see Alvotech handling the development and commercial supply, while Advanz Pharma will manage registration and commercial efforts. The partnership, including prior agreements covering multiple biosimilars, now addresses an addressable market of at least $13.8 billion. The companies are aiming for a launch starting in 2025 and extending towards 2030.
Read more →ALVO▲ +10.2%on this newsshared move
Alvotech Announces the Outcome of the Offering in Connection with the Company's Listing on Nasdaq Stockholm
Alvotech has announced a successful outcome for its offering of Swedish Depository Receipts (SDRs) in connection with its listing on Nasdaq Stockholm. The offering, which took place from May 9 to 16, 2025, was multiple times oversubscribed, leading to over 3,000 new shareholders. Trading of the SDRs is set to commence on May 19, 2025, with gross proceeds of approximately SEK 39 million. This move is part of Alvotech's strategy to expand its research and development capabilities and increase its presence in the Nordic biotech market.
Read more →ALVO▲ +10.2%on this newsshared move
Alvotech Annual General Meeting to be held June 25, 2025
Alvotech has announced that its Annual General Meeting will take place on June 25, 2025, at 9:00 a.m. CEST. The meeting will be located at Arendt & Medernach in Luxembourg. Attendees can find the final agenda and additional details on Alvotech's official investor website.
Read more →ALVOAlvotech Appoints DNB Carnegie as Liquidity Provider on Nasdaq Stockholm
Alvotech has appointed DNB Carnegie as its liquidity provider for Swedish Depository Receipts traded on Nasdaq Stockholm, effective May 20, 2025. This agreement aims to ensure liquidity in the SDRs by having DNB Carnegie continuously quote prices, thus reducing the spread between buying and selling prices. Alvotech, focused on developing biosimilars, continues to expand its influence in the global market with a pipeline of biosimilar candidates targeting various diseases and established partnerships across multiple countries.
Read more →ALVOAlvotech Announces the Outcome of the Offering in Connection with the Company’s Listing on Nasdaq Stockholm
Alvotech has announced the successful outcome of its Offering of Swedish Depository Receipts (SDRs) in relation to its listing on Nasdaq Stockholm. The Offering, which ran from May 9-16, 2025, saw strong public interest and was oversubscribed, resulting in over 3,000 new shareholders. The listing is expected to improve Alvotech's visibility in the Nordic market and facilitate greater access to regional capital. Trading in the SDRs is set to commence on May 19, 2025.
Read more →ALVOAlvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
Alvotech (NASDAQ: ALVO) announced its participation in the BofA Securities Healthcare Conference 2025, scheduled for May 13-15, 2025, in Las Vegas. The company's management will engage in one-on-one meetings and participate in a fireside chat on May 14. A live audio webcast of the chat will be available, along with a recording accessible for 90 days post-event. Alvotech focuses on developing biosimilar medicines and has launched two products, with an expansive pipeline targeting various diseases.
Read more →ALVO▲ +18.1%on this news· ran to +33% by day 3shared move
Alvotech Publishes Prospectus in Connection with its Listing on Nasdaq Stockholm
Alvotech plans to list Swedish Depository Receipts (SDRs) on Nasdaq Stockholm, with trading expected to begin on May 19, 2025. This move follows the acquisition of Xbrane Biopharma's R&D operations and aims to expand the company's investor base in Europe. The Offering, projected to raise about SEK 30 million, will only be available to investors in Sweden. Given strong investor interest in European biotech, Alvotech's listing could enhance its profile in the continental market.
Read more →ALVOAlvotech Reports Results for the First Quarter of 2025 and Provides Business Update
Alvotech reported its financial results for Q1 2025, highlighting a substantial increase in total revenues to $132.8 million, a 260% rise compared to the same quarter last year. The adjusted EBITDA also turned positive at $20.5 million, in stark contrast to the previous year's losses, prompting an increase in full-year revenue guidance to between $600-700 million. Key developments included the successful launch of the SELARSDI biosimilar and the acceptance of multiple Biologics License Applications. The company’s financial health is improving, aided by a strong response to its acquisitions and new product launches.
Read more →ALVOAlvotech Announces Webcast of First Quarter 2025 Financial Results on May 8, 2025, at 8:00 am EDT (14:00 CET)
Alvotech has announced it will release its financial results for the first quarter of 2025 after the U.S. markets close on May 7, 2025. A conference call will be held on May 8, 2025, to discuss these results and provide insights into recent business developments. The proceedings will be accessible to the public via a live audio webcast. The company remains focused on increasing its market presence in the biosimilars sector with an existing product pipeline and various strategic partnerships.
Read more →ALVO▼ -10.3%on this news
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
Alvotech has appointed Dr. Balaji V. Prasad as its new Chief Strategy Officer. Dr. Prasad possesses 25 years of experience in the pharmaceutical industry, including roles as a consultant and equities analyst. His expertise is expected to enhance Alvotech's growth and strengthen its position in the biosimilars market. The company currently has two approved biosimilars and a robust pipeline of candidates aimed at various medical conditions.
Read more →ALVOAlvotech Reports Record Results for 2024 and Provides Business Update
Alvotech reported unprecedented financial results for 2024, with total revenues of $492 million, reflecting a 427% increase year-over-year. The company's adjusted EBITDA turned positive at $108.3 million, a substantial improvement from substantial losses in 2023. Alvotech's successful submissions of three new biosimilar applications show promising growth potential in global markets. The company also announced plans for future business developments, including acquisitions that aim to enhance their R&D capabilities.
Read more →ALVOAlvotech Acquires Xbrane’s R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
Alvotech has announced the acquisition of Xbrane Biopharma's R&D operations and its biosimilar candidate XB003, further solidifying its position in the biosimilars market. This move aims to enhance Alvotech’s development capabilities and establish a presence in Sweden’s life science sector. The acquisition involves a total value of approximately SEK 275 million and will be paid partly in cash and partly through the assumption of debt. Approval from Xbrane's shareholders and regulatory authorities is required to complete the transaction, targeted for April 2025.
Read more →ALVOAlvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia and Xgeva
Alvotech and Dr. Reddy's Laboratories have reported that the FDA has accepted the Biologic License Application for AVT03, a proposed biosimilar to Prolia and Xgeva. This milestone signifies progress in providing a more affordable therapeutic option for patients requiring treatment for osteoporosis and other bone diseases. Under their License and Supply Agreement, Alvotech will manage the product's development and manufacturing, while Dr. Reddy's will focus on registration and commercialization in the U.S. The product aims to deliver significant benefits to the healthcare system upon approval.
Read more →ALVOAlvotech Meeting Investors and Participates in Fireside Chat At Barclays 27th Global Healthcare Conference in Miami, Florida
Alvotech (NASDAQ: ALVO) announced its upcoming participation in the Barclays 27th Annual Global Healthcare Conference in Miami, Florida, scheduled for March 11-13, 2025. The event will feature one-on-one meetings hosted by CEO Robert Wessman and a fireside chat on March 12. An audio webcast will be available for public access, alongside a recording for later viewing. Alvotech aims to strengthen its position in the biosimilar market with a robust pipeline targeting various diseases and a network of strategic commercial partnerships.
Read more →ALVOAlvotech to Report Full Year Financial Results for 2024 on March 26, 2025, and Hosts Conference Call on March 27, 2025, at 8:00 am ET
Alvotech (NASDAQ: ALVO) has announced that it will release its full year financial results for 2024 on March 26, 2025. Following the results announcement, a conference call will be held for analysts on March 27, 2025, at 8:00 am ET. Additionally, Alvotech will host a local investor event in Reykjavik the same day, which will be conducted in Icelandic. Alvotech continues to focus on the development of biosimilar medicines with multiple products already in the market and further candidates in its pipeline.
Read more →ALVOAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea (aflibercept)
Alvotech and Teva Pharmaceuticals have announced that the FDA has accepted the Biologics License Application for AVT06, a proposed biosimilar to Eylea. This acceptance marks a critical step towards gaining regulatory approval, which is anticipated by the fourth quarter of 2025. Alongside AVT06, Alvotech is also developing another biosimilar, AVT29, targeting Eylea HD. The acceptance not only indicates progress in Alvotech's agenda but also emphasizes the shared commitment between Alvotech and Teva to enhance patient access to treatment for eye disorders.
Read more →ALVOAlvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi and Simponi Aria (golimumab)
Alvotech and Teva Pharmaceuticals have announced that the FDA has accepted for review the Biologics License Applications for AVT05, their proposed biosimilar to Simponi and Simponi Aria (golimumab). This marks the first acceptance of BLA filings for a biosimilar candidate to golimumab in the U.S. The FDA review is expected to be completed by Q4 2025. The acceptances follow positive results from clinical studies, indicating robust efforts in developing effective biosimilar treatments for inflammatory conditions.
Read more →ALVO▲ +5.1%on this news
Alvotech Added to Nasdaq Biotech Index Effective Monday December 23, 2024
Alvotech has announced that it will be added to the Nasdaq Biotechnology Index effective December 23, 2024. This inclusion is part of the annual reconstitution of the index, highlighting Alvotech's qualifications based on market capitalization and trading volume. As a developer of biosimilar medicines, Alvotech aims to establish itself as a leader in the biosimilar space, with a robust pipeline of products and strategic partnerships across various markets.
Read more →ALVOAlvotech Reports Financial Results for the First Nine Months of 2024
Alvotech reported robust financial results for the first nine months of 2024, showing a significant rise in total revenues to $339 million, primarily driven by a four-fold increase in product revenues. Adjusted EBITDA soared to $87 million, contrasting favorably with a loss in the prior year. The company has made notable progress in its biosimilar pipeline, with marketing applications accepted in Europe and a new confirmatory clinical study underway for one of its products. Overall, the results reflect Alvotech's successful expansion and operational improvements.
Read more →ALVOAlvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024
Alvotech, a biotech company specializing in biosimilars, announced its participation in two upcoming healthcare conferences: Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024. The management team will conduct one-on-one meetings and host a fire-side chat during the HealthCONx Conference. A live audio webcast of the fire-side chat will be available for public access, enhancing investor engagement. Alvotech's current pipeline includes nine biosimilar candidates targeting various medical conditions.
Read more →ALVOAlvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET
Alvotech (NASDAQ: ALVO) will release its financial results for the first nine months of 2024 on November 13, 2024, after market close. A conference call is scheduled for the following day to discuss these results and recent business developments. The event will be accessible via webcast and will be archived for 90 days, aiming to engage analysts, investors, and the public. Alvotech focuses on biosimilar medicines and has a robust development pipeline including nine candidates targeting various diseases.
Read more →ALVOAlvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024
Alvotech (NASDAQ: ALVO) is set to participate in the Jefferies London Healthcare Conference on November 19-20, 2024. The biotechnology company will host one-on-one meetings with investors and present on November 19 at 9:00 am GMT. An audio webcast of the presentation will be accessible to the public and available for 90 days post-event. Alvotech aims to lead the biosimilar market with a robust pipeline and numerous global partnerships.
Read more →ALVOAlvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara (ustekinumab)
Alvotech and Teva have received U.S. FDA approval for SELARSDI in a new presentation, allowing intravenous infusion for treating Crohn's disease and ulcerative colitis. This new indication aligns SELARSDI more closely with its reference product, Stelara. SELARSDI's U.S. launch is expected in the first quarter of 2025, following previously approved subcutaneous formulations. The collaboration between Alvotech and Teva is set to enhance access to biosimilar treatments across the United States and beyond.
Read more →ALVOAlvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio
Alvotech announced the initiation of a confirmatory patient study for AVT16, a proposed biosimilar to Entyvio, aimed at evaluating its comparative efficacy and safety in treating moderate to severe Ulcerative Colitis. This double-blind study will follow participants receiving either AVT16 or Entyvio, with results expected to define the treatment's effectiveness. The study contributes to Alvotech's expanding pipeline of biosimilars, which includes several other candidates already in development. However, AVT16 remains an investigational product without regulatory approval or confirmed biosimilarity at this stage.
Read more →ALVOAlvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Alvotech (NASDAQ: ALVO) will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference, which will take place in New York on September 5, 2024. Members of the management team will hold an in-person fireside chat during the event. A live audio webcast will be available for access during or after the chat, with recordings archived for at least 90 days. Alvotech focuses on developing biosimilar medicines and currently has two launched products with nine more in development.
Read more →ALVO▲ +8%on this news
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024
Alvotech reported unprecedented financial results for the first half of 2024, achieving record revenues of $236 million, a remarkable increase compared to the previous year. The company's adjusted EBITDA turned positive for the first time, reaching $64 million, as product revenues surged and significant milestone earnings were recognized. Alvotech also announced the acceptance of its EU marketing application for its biosimilar AVT06, further solidifying its position in the biosimilar market. The company is actively launching new products and expanding its strategic partnerships.
Read more →ALVOAlvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
Alvotech (NASDAQ: ALVO) plans to report its financial results for the first half of 2024 on August 15, 2024, after the U.S. market closes. A conference call to discuss these results and business highlights will be held on August 16, 2024, at 8:00 am EDT. The event will be available as a live webcast and will be archived for 90 days for replay. Alvotech continues to focus on the development of biosimilar medicines and has established partnerships for wider market reach.
Read more →ALVOAlvotech Announces Closing of Private Debt Financing
Alvotech has successfully closed a $965 million senior secured term loan facility, allowing the company to refinance existing debt and enhance its capital structure. This refinancing is expected to lower Alvotech's cost of capital and improve its overall debt maturity profile. The company now holds $1,035 million in gross borrowings and $185 million in cash, which will support ongoing and future biosimilar launches. Alvotech aims to utilize this financial support to advance its development pipeline, which includes nine biosimilar candidates targeting various therapeutic areas.
Read more →ALVOAlvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva
Alvotech announced positive topline results from its confirmatory patient study for AVT03, a proposed biosimilar to Prolia and Xgeva. The study successfully demonstrated clinical similarity between AVT03 and Prolia in terms of efficacy and safety for postmenopausal women with osteoporosis. Furthermore, two pharmacokinetics studies comparing AVT03 to Prolia and Xgeva met their primary endpoints. Alvotech expects to file marketing applications for AVT03 in major global markets later this year.
Read more →ALVOAlvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024
Alvotech (NASDAQ: ALVO) announced strong preliminary financial results for Q2 2024, estimating revenues between $196 and $201 million and an adjusted EBITDA of $98 to $103 million. This reflects a significant year-over-year growth, including a marked increase in product revenues from sales of its biosimilars. Key revenue drivers included milestone revenues due to positive clinical results and the launch of new products. However, these figures remain preliminary and unverified, underscoring the potential for variability in final results.
Read more →ALVOAlvotech Issues New Shares to Holders of Convertible Bonds
Alvotech (NASDAQ: ALVO) has issued 22,073,578 new ordinary shares to holders of subordinated convertible bonds at a fixed price of $10.00 per share. This issuance comes as part of the company's ongoing strategy to convert Convertible Bonds into equity, enhancing its capital structure. After this conversion, Alvotech will have a total of 324,801,040 issued shares, signifying growth in its shareholder base. The company, dedicated to the development of biosimilar medicines, has an active pipeline featuring nine candidates targeting various diseases.
Read more →ALVO▼ -5.9%on this newsshared move
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
Alvotech has announced that the majority of holders of its subordinated convertible bonds have elected to convert their bonds into ordinary shares at a fixed price of $10.00 per share. This conversion will result in the issuance of approximately 22.1 million new shares, depending on the prevailing exchange rate before the conversion date. The company highlights a robust support from its Tranche A Bonds, though some USD denominated bonds remain unconverted. Overall, the conversion is seen as a step towards strengthening Alvotech's capital and market position.
Read more →ALVOAlvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea LD/HD in Europe
Alvotech and Advanz Pharma have announced a strategic commercialization agreement for Alvotech's proposed biosimilars AVT06 and AVT29, which target Eylea® in Europe. As part of this exclusive partnership, Advanz Pharma will handle registration and marketing activities, allowing Alvotech to focus on development and supply. The agreement includes an upfront payment and milestone payments, highlighting mutual commitment to increasing access to affordable biologics for patients. This collaboration builds on previous agreements between the two companies and indicates a strengthening relationship in the biosimilars market.
Read more →ALVOCautionary Note Regarding Forward Looking Statements This Exhibit contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements g
Alvotech issued a cautionary note highlighting forward-looking statements that describe its future performance expectations and potential risks. The company detailed its strategic plans concerning capital raising, regulatory approvals, and the commercialization of its biosimilar product candidates. Recent agreements with partners such as Teva, Dr. Reddy's Laboratories, and STADA further expand Alvotech's market presence and product availability. However, risks associated with funding, regulatory conditions, and operational challenges remain significant.
Read more →ALVOAlvotech and STADA add to Strategic Alliance through Denosumab Partnership
Alvotech has entered into an expanded partnership with STADA to develop and market AVT03, a biosimilar referencing denosumab, a treatment for osteoporosis and cancer-related bone loss. This collaboration builds on their existing alliance in Europe and aims to make high-quality biosimilars more accessible. Under the agreement, Alvotech will handle the development and manufacturing, while STADA will manage marketing authorization and commercial rights in Europe and select markets. The partnership reflects both companies' commitment to addressing the needs of patients in these therapeutic areas.
Read more →ALVOAlvotech Announces Strategic Refinancing Agreement
Alvotech has entered a strategic refinancing agreement with GoldenTree Asset Management and other investors, securing up to $965 million to improve its financial positioning. This facility is intended to address upcoming debt maturities in 2025 and provide additional working capital for product launches. Alvotech's leadership expresses optimism about future revenue growth and the success of its biosimilars pipeline. However, the company faces inherent risks associated with maturing debt obligations and the need for sustained funding to support its operations.
Read more →ALVOAlvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
Alvotech, a biotechnology firm focused on biosimilar medicines, announced its participation in the Jefferies Healthcare Conference scheduled for June 5-6, 2024, in New York. At the conference, Chief Business Officer Anil Okay will present on June 6, with a live audio webcast available for participants. The event is expected to enhance Alvotech's visibility and investor engagement, alongside showcasing its current pipeline of eight biosimilar candidates addressing multiple health conditions.
Read more →ALVOAlvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
Alvotech reported financial results for Q1 2024, indicating a substantial increase in total revenues to $37 million compared to $16 million in the prior year. The company also raised its revenue guidance for 2024 to a range of $400-$500 million and announced positive developments in its biosimilar product pipeline, including FDA approvals and strategic partnerships. However, despite the revenue growth, Alvotech reported a net loss of $218.7 million for the quarter, highlighting ongoing financial challenges.
Read more →ALVOAlvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia & Xgeva in the U.S., Europe and UK
Alvotech has entered into a collaboration with Dr. Reddy's Laboratories to commercialize AVT03, a biosimilar candidate to Prolia and Xgeva. Under the agreement, Dr. Reddy's obtains exclusive commercialization rights in the U.S. and semi-exclusive rights in Europe and the UK. Alvotech will handle the development and manufacturing, while Dr. Reddy's will oversee registration and commercialization. This partnership aims to enhance access to biosimilar therapies and is expected to support both companies' growth in regulated markets.
Read more →ALVOAlvotech S.A. Annual General Meeting to be held June 7, 2024
Alvotech S.A. has announced that its Annual General Meeting will take place on June 7, 2024, at 09:00 a.m. CEST in Luxembourg. The meeting will be held at the office of Arendt & Medernach S.A. Additionally, all relevant materials and additional information regarding the meeting are accessible via the company's website. This event will allow shareholders to engage directly with the company's leadership.
Read more →ALVOAlvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
Alvotech has announced the release of its financial results for the first quarter of 2024 on May 21, 2024, following U.S. market closure. A conference call will be held on May 22, 2024, to present the results and share business updates. The event will be webcast live for media, investors, and the public, with future access to archived content. Alvotech focuses on creating biosimilar medicines and maintains a robust pipeline of candidates across various therapeutic areas.
Read more →ALVOAlvotech Announces Participation at BofA Securities Healthcare Conference 2024
Alvotech (NASDAQ: ALVO) will participate in the BofA Securities Healthcare Conference 2024, scheduled for May 14-15 in Las Vegas. Members of Alvotech's management team plan to host one-on-one meetings with investors during the event. The company, focused on biosimilars, aims to strengthen its position in the market through its ongoing development pipeline and strategic partnerships across various global regions.
Read more →ALVOAlvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi (golimumab)
Alvotech has announced positive topline results from a confirmatory clinical study for AVT05, a proposed biosimilar to Simponi, showing it met the primary endpoint in patients with moderate to severe rheumatoid arthritis. This marks Alvotech as the first company to report such results for a biosimilar candidate to Simponi. The study demonstrated therapeutic equivalence between AVT05 and the reference product, with no significant safety concerns reported. Alvotech plans to file marketing applications for AVT05 in major global markets this year, bolstering its biosimilar pipeline.
Read more →ALVOAlvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira (adalimumab)
Alvotech has signed a long-term agreement with a strategic partner to market its newly FDA-approved high-concentration interchangeable biosimilar to Humira in the U.S. This partnership aims to broaden patient access to Adalimumab-ryvk, reflecting Alvotech's commitment to providing affordable healthcare solutions. The existing commercialization arrangement with Teva Pharmaceuticals will remain unchanged, allowing continued distribution under the SIMLANDI brand. Alvotech's strategy emphasizes collaboration and quality products to enhance its presence in the biosimilar market.
Read more →ALVOAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)
Alvotech and Teva Pharmaceuticals have received FDA approval for SELARSDI (ustekinumab-aekn), a biosimilar to Stelara, for treating moderate to severe plaque psoriasis and active psoriatic arthritis in both adults and pediatric patients. This approval represents the second biosimilar from their strategic partnership and is expected to launch in the U.S. by February 21, 2025. The use of the same cell type and manufacturing process as Stelara facilitated its development, and the introduction of SELARSDI is anticipated to lower healthcare costs while offering additional treatment options for patients.
Read more →ALVOAlvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
Alvotech (NASDAQ: ALVO) announced it will hold an audio investor call on April 3, 2024, at 8:15 am EDT. The call will feature a market update from Chief Commercial Officer Anil Okay. The investor presentation will have a live webcast available, and it will be archived for 90 days. Alvotech focuses on developing biosimilars, indicating ongoing efforts to enhance its product pipeline and commercial footprint through strategic partnerships worldwide.
Read more →ALVOAlvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Alvotech reported a 10% overall revenue increase to $93.4 million in 2023, with product revenues doubling to $48.7 million. The company received FDA approval for Simlandi™, making it the first interchangeable biosimilar to Humira® in the U.S. Additionally, sales of Jamteki™, a biosimilar to Stelara®, commenced successfully in Canada, with expansions planned for Japan and Europe. Despite these advancements, the company faced challenges, including higher costs associated with product launches and increased R&D expenses.
Read more →ALVOAlvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
Alvotech announced its plans to release the financial results for the full year 2023 on March 20, 2024. Following the release, a conference call will take place on March 21, 2024, available via live webcast. Additionally, the company will host a Capital Markets Day on March 22, 2024, in Reykjavik and online, focusing on its business strategy and pipeline activities.
Read more →ALVOAlvotech Appoints Interim Chief Quality Officer
Alvotech has appointed Christina Siniscalchi as its interim Chief Quality Officer, succeeding Sandra Casaca amid organizational changes. Siniscalchi brings over ten years of experience in quality positions at Alvogen, including most recently as Chief Quality Officer. This leadership change aims to strengthen Alvotech's commitment to quality and compliance as the company prepares for multiple product launches worldwide. The announcement follows the successful FDA inspection that facilitated the approval of a high-concentration biosimilar to Humira in the U.S.
Read more →ALVO▲ +7.7%on this newsshared move
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
Alvotech (NASDAQ: ALVO) has accepted an offer for the sale of 10,127,132 ordinary shares, approximately valued at USD 166 million. The shares will be sold at a price of USD 16.41 each, and the transaction will occur on the Nasdaq Iceland Exchange. Proceeds from this sale are earmarked for general corporate purposes, including enhancing production capabilities and facilitating expected biosimilar launches. This deal reflects investor interest in Alvotech's growth potential in the biosimilar market.
Read more →ALVO▲ +7.7%on this newsshared move
Alvotech and Teva Announce U.S. Approval of SIMLANDI (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira
Alvotech and Teva Pharmaceuticals have received U.S. FDA approval for SIMLANDI (adalimumab-ryvk), marking it as the first high-concentration, citrate-free biosimilar to Humira with interchangeable status. This approval allows SIMLANDI to be substituted at pharmacies, potentially increasing access to multiple treatment options for patients with conditions like rheumatoid arthritis and Crohn's disease. The partnership between Alvotech and Teva is strategic in developing biosimilars, emphasizing their commitment to making treatments more affordable and accessible in the healthcare system.
Read more →ALVOAlvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara (ustekinumab)
Alvotech (NASDAQ: ALVO) announced the expected global market entry dates for its biosimilar AVT04, which is aimed at providing a lower-cost alternative to Stelara (ustekinumab). The company has secured regulatory approval in Japan, Canada, and the European Economic Area, with plans for market entry in Canada in Q1 2024 and Japan by May 2024. Additionally, Alvotech has projected entry to European markets following the expiration of exclusivity in late July 2024. The U.S. launch is anticipated by February 2025 pending FDA approval, emphasizing Alvotech's commitment to expanding access to vital biologics.
Read more →ALVOAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva
Alvotech announced positive top-line results from a pharmacokinetic study (AVT03-GL-P01) of AVT03, a proposed biosimilar to Prolia and Xgeva. The study demonstrated the pharmacokinetics, safety, and tolerability of AVT03, meeting its primary endpoints. A confirmatory efficacy study in patients is currently underway, along with another PK study comparing AVT03 to Xgeva. Alvotech is focused on developing cost-effective biosimilars to improve patient access to essential treatments.
Read more →ALVO▲ +15.3%on this news
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
Alvotech has concluded a reinspection of its facility in Iceland by the FDA, having received one observation on a form 483. The company is confident that this observation is addressable and intends to respond quickly. Alvotech aims to secure approval for its biosimilars AVT02 and AVT04 by February and April 2024, respectively. With a focus on biosimilars and a network of global partnerships, Alvotech is positioning itself as a leader in the sector.
Read more →ALVOAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea (aflibercept)
Alvotech announced positive results from its confirmatory clinical study for AVT06, a biosimilar candidate to Eylea, which met its primary endpoint in patients with wet AMD. The study showed therapeutic equivalence between AVT06 and Eylea, indicating the potential for Alvotech's biosimilar in treating eye disorders. The company emphasized its integrated development and manufacturing platform that supports the rapid advancement of multiple biosimilars. However, it's important to note that AVT06 has not yet received regulatory approval.
Read more →ALVOAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria
Alvotech announced positive top-line results from a pharmacokinetic study of AVT05, a proposed biosimilar for Simponi and Simponi Aria. The study successfully met its primary endpoint, indicating the safety and tolerability of AVT05 in healthy adults. This achievement highlights Alvotech's commitment to expanding access to affordable biosimilar medicines. In addition, AVT05 is a key part of Alvotech's pipeline aimed at chronic inflammatory diseases.
Read more →ALVOAlvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update
Alvotech has reported notable financial results for the first nine months of 2023, with product revenue increasing to $29.8 million compared to $11.1 million in the same period last year. The company received marketing authorizations for AVT04, a biosimilar to Stelara, in both Canada and Japan, and has a positive opinion from the European Medicines Agency for further authorization in Europe. However, the approval of AVT02 and AVT04 in the U.S. is contingent on the outcome of a scheduled FDA inspection in January 2024, highlighting potential risks ahead.
Read more →ALVOAlvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
Alvotech (NASDAQ: ALVO) announced it will report its financial results for the first nine months of 2023 on November 28, 2023. Following this release, the company will host a business update conference call on November 29, 2023, at 8:00 am ET. The call will be accessible via a webcast, providing an avenue for analysts, investors, and the public to engage with the company's updates. Alvotech specializes in developing biosimilar medicines and aims to solidify its global presence in this market.
Read more →ALVOAlvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara (ustekinumab)
Alvotech and JAMP Pharma have received marketing authorization from Health Canada for AVT04, a biosimilar to Stelara (ustekinumab) branded as JamtekiTM. This marks the second biosimilar developed under their partnership to receive such authorization. The commercial launch of JamtekiTM emphasizes their shared dedication to enhancing patient access to effective and affordable biosimilar treatments in Canada. The duo's previous success with another biosimilar, SimlandiTM, underlines their strategic collaboration in the biosimilar market.
Read more →ALVOAlvotech to Present at the Jefferies 2023 London Healthcare Conference
Alvotech announced its participation in the Jefferies 2023 London Healthcare Conference scheduled for November 14-16, 2023, with a presentation on November 15. The event will be accessible via a webcast, allowing investors to follow the presentation online. Alvotech continues to expand its presence in biosimilar medicines, showcasing its pipeline of eight candidates targeting various medical conditions.
Read more →ALVOAlvotech Provides Update on Status of U.S. Biologics License Application for AVT04
Alvotech announced that the FDA has issued a complete response letter for its Biologics License Application for AVT04, a biosimilar candidate to Stelara. The CRL cited deficiencies identified during an inspection of Alvotech's Reykjavik facility. The company plans to address these issues and resubmit the application, beginning a new review period. AVT04 has been approved in Japan and is undergoing evaluation in other major markets. Alvotech expects to have AVT04 available for U.S. patients by February 2025, contingent upon satisfactory inspection and approval.
Read more →ALVOAlvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland
Alvotech has announced a market making agreement with Íslandsbanki for its shares trading on Nasdaq Iceland. Under this arrangement, Íslandsbanki will actively post bids and offers to improve liquidity, ensuring that at least ISK 8 million is available at any given time with controlled price spreads. The agreement, effective from October 6, 2023, aims to make the trading of ALVO shares more efficient, although it remains subject to specific trading conditions. Previous agreements with other banks continue to remain active, ensuring broader market support for Alvotech's trading activities.
Read more →ALVOAlvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair (omalizumab)
Alvotech has announced an exclusive licensing agreement with Kashiv BioSciences for the development and commercialization of AVT23, a proposed biosimilar to Xolair (omalizumab). This strategic partnership covers significant markets such as the European Union, UK, Australia, Canada, and New Zealand. Under this agreement, Alvotech will manage the commercialization, while Kashiv will be responsible for development and manufacturing. This collaboration is expected to facilitate patient access to this biosimilar treatment, leveraging both companies' strengths in the industry.
Read more →ALVOAlvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara
Alvotech has announced that its commercialization partner, Fuji Pharma, received marketing approval for AVT04, a biosimilar to Stelara, from the Japanese Ministry of Health, Labor and Welfare. This represents the first global approval for a biosimilar of Stelara, which has generated over $10 billion in sales. Alvotech is excited about enhancing patient access to biologic medicines in Japan and continues to work on several other biosimilar candidates. The Sp2/0 host cell line used for AVT04 contributes to its effective development and manufacturing process.
Read more →ALVOAlvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira (adalimumab)
Alvotech announced that the FDA has accepted its resubmitted Biologics License Application (BLA) for AVT02, a high-concentration interchangeable biosimilar candidate to Humira. The FDA has set a goal date for the approval of this BLA on February 24, 2024. Alvotech's resubmission was considered a complete response to previous agency feedback concerning manufacturing deficiencies. The company aims to address a significant unmet need for biosimilars in the U.S. market.
Read more →ALVOAlvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Alvotech (NASDAQ: ALVO) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference in New York from September 11-13, 2023. Ming Li, the Chief Strategy Officer, is scheduled to hold a fireside chat on September 13, at 12:30 pm EDT. The event will be available via a live audio webcast, which can be accessed from Alvotech's website. The company is focused on developing biosimilar medicines and currently has eight candidates in its pipeline targeting various diseases.
Read more →ALVOAlvotech Unaudited Condensed Consolidated Interim Financial Statements as of 30 June 2023 and for the six months ended 30 June 2023 and 30 June 2022 Alvotech 9, rue de Bitbourg L-1273 Luxembourg Grand Duchy of Luxembourg
Alvotech reported its unaudited financial results for the six months ending on June 30, 2023, highlighting a net loss of $86.9 million. This marks an improvement compared to a net loss of $184.5 million in the same period of 2022. The company successfully launched the AVT02 product but faced regulatory challenges, receiving two complete response letters from the FDA for its BLA applications due to facility deficiencies. Additionally, the overall revenue composition revealed a significant decrease in licensing revenue coupled with increased R&D expenses.
Read more →ALVOAlvotech Announces Changes to the Leadership Team REYKJAVIK, ICELAND (
Alvotech has appointed Faysal Kalmoua as Chief Operating Officer, marking a significant leadership change following the resubmission of the Biologics License Application for its biosimilar AVT02. Kalmoua brings a wealth of experience from his previous roles within Alvotech and other pharmaceutical companies. The leadership transition comes at a crucial time as the company aims to navigate regulatory challenges and enhance its position in the biosimilars market. Despite positive sentiments surrounding the new appointment, the departure of Hafrun Fridriksdottir raises concerns about leadership stability.
Read more →ALVOAlvotech Announces Changes to the Leadership Team
Alvotech announced changes to its leadership team with the appointment of Faysal Kalmoua as the new Chief Operating Officer. Kalmoua, who previously held a senior management role and has been with the company since 2020, replaces Hafrun Fridriksdottir, who is stepping down following the resubmission of the Biologics License Application for its biosimilar drug AVT02. The company expressed confidence in Kalmoua's capabilities and aims to further develop its pipeline of biosimilar medicines while enhancing its global presence in the market. Challenges remain, as they must address FDA inspection findings and fulfill various regulatory expectations.
Read more →ALVOAlvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
Alvotech reported financial results for the first half of 2023, showing a substantial increase in product revenue to $22.7 million from $3.9 million a year prior. The company also expanded its partnerships with Teva Pharmaceuticals and Advanz Pharma, securing additional commercialization agreements. A settlement with Johnson & Johnson provided a license entry date for their biosimilar AVT04, while the firm also faces challenges, including a significant loss and unresolved issues raised by the FDA regarding AVT02. A business update conference call is scheduled for August 31, 2023, to provide further insights.
Read more →ALVOAlvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
Alvotech and Bioventure have announced the approval of AVT02 (adalimumab) in Egypt by the Egyptian Drug Authority. This biosimilar, which is similar to Humira, aims to enhance patient access to affordable treatments for rheumatoid arthritis and other inflammatory diseases. The approval marks a significant milestone in their partnership, which has previously secured approval in Saudi Arabia as well. Alvotech is committed to developing biosimilars to increase global healthcare accessibility.
Read more →ALVOAlvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
Alvotech will announce its financial results for the first half of 2023 on August 30, 2023. Following this announcement, a business update conference call will take place on August 31, 2023, at 8:00 am ET. The event will be accessible via a live webcast, open to analysts, investors, and the general public. Alvotech specializes in the development of biosimilar medicines and holds a pipeline of eight candidates aimed at treating various medical conditions.
Read more →ALVOAlvotech or its partners to gain approval from regulators for planned clinical studies, study plans or sites; (12) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinic
Alvotech has announced the completion of a $100 million private placement of subordinated convertible bonds aimed at financing its biosimilar development pipeline. The bonds will mature on December 20, 2025, and may be converted into Alvotech shares at a rate of $10 per share by the end of this year. While the company enjoys strong partnerships globally, it faces risks related to regulatory approvals and market conditions that could impact its strategic goals.
Read more →ALVOAlvotech Completes $100 Million Convertible Bond Private Placement
Alvotech has successfully completed a private placement of subordinated convertible bonds totaling $100 million, directed mainly to professional clients in Iceland. The funds raised will be utilized for the continued development of the company's biosimilars pipeline. ATP Holdings ehf., a significant shareholder, has committed to acquiring any unsold bonds, ensuring full subscription of the offering. Settlement is expected to occur on August 11, 2023, with bondholders having the option to convert their bonds into shares in late 2023 or mid-2024.
Read more →ALVOImportant factors that could cause or contribute to such differences include: risks relating to the expansion of our strategic partnership with Alvotech and the ability to achieve expected results from investments in bio
Teva Pharmaceuticals and Alvotech are expanding their strategic partnership to enhance the commercialization efforts of biosimilar medicines. The agreement includes exclusive rights for Teva to commercialize two new biosimilar candidates in the U.S. while also facilitating shared profits. Teva is investing $40 million in subordinated convertible bonds to support Alvotech's biosimilars pipeline, which includes ongoing regulatory approvals for products like AVT02 and AVT04. Both companies express confidence in their collaborative efforts to bring these products to market successfully.
Read more →ALVOCERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THE OMISSIONS HAVE BEEN INDICATED BY "[***]". TERM
Alvotech and Stada have entered into a Termination Agreement, mutually agreeing to terminate the Vedolizumab Agreement. The decision is articulated in a formal document that outlines the terms of the termination. Both companies are represented in the agreement by their executives, signaling a potential shift in their collaboration strategies. Though the reasons behind the termination are not detailed in the extract, this marks a noteworthy change in Alvotech's partnerships.
Read more →ALVOAlvotech Provides Regulatory Update on Second Biologics License Application for AVT02
Alvotech has received a complete response letter from the FDA regarding its second Biologics License Application for AVT02, a biosimilar candidate for Humira. The letter highlighted deficiencies found during an inspection of the company’s Reykjavik facility that need to be resolved before approval. Despite this setback, Alvotech plans to resubmit the application and has also secured interest from its major shareholder for financing. The company aims to address these issues and continue developing its product pipeline of biosimilar candidates.
Read more →ALVO▲ +7.8%on this news
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara According to the settlement agreement, AVT04 (ustekinumab) can be marketed in the US, subject to regulatory approval, no later than
Alvotech and Teva Pharmaceuticals have reached a settlement agreement with Johnson & Johnson, allowing Alvotech's proposed biosimilar AVT04 to be marketed in the U.S. by February 21, 2025, pending regulatory approval. This milestone marks Alvotech's second biosimilar candidate entering the U.S. market. The agreement underscores both companies' commitment to reducing healthcare costs through biosimilars, with AVT04 targeting inflammatory and immune responses. While AVT04 has not yet received regulatory approval, the license indicates potential market interest.
Read more →ALVOAlvotech Soci t anonyme Gesellschaftssitz: 9, rue de Bitbourg, L-1273 Luxembourg R.C.S. Luxemburg B 258884 HAUPTVERSAMMLUNG DER AKTIONÄRE vom 6. Juni 2023 Nummer In the year two thousand and twenty-three, on the six
Alvotech held its annual general meeting on June 6, 2023, in Luxembourg, where several resolutions were passed. Most notably, the company approved its annual financial statements, which revealed a total balance sheet of USD 2,187,299,420 and noted a loss of USD 30,520,327 for the previous financial year. Additionally, shareholders approved the renewal of Deloitte Audit as independent auditor and the remuneration policy for the Board of Directors, which takes effect immediately. The meeting achieved a quorum with 77.06% of voting shares represented.
Read more →ALVOAlvotech to Participate in Jefferies Healthcare Conference
Alvotech, a biotech company focused on biosimilars, announced its participation in the Jefferies Healthcare Conference in New York on June 7, 2023. Chief Commercial Officer Anil Okay is set to present during the event, and a webcast will be available for those unable to attend. The company's current pipeline includes eight biosimilar candidates targeting various medical conditions, indicating its commitment to becoming a leader in the biosimilar market through strategic partnerships and innovative development.
Read more →ALVOAlvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe - Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in Europe - T
Alvotech and Advanz Pharma have announced the extension of their strategic partnership to focus on the commercialization of five proposed biosimilars in Europe. Under this exclusive agreement, Alvotech will handle development and supply, while Advanz Pharma will manage registration and commercialization. This collaboration aims to improve patient access to affordable biologics and strengthens Advanz's position in the European biosimilars market. The biosimilars included in the agreement target notable treatments, contributing to an addressable market exceeding $4 billion.
Read more →ALVOAlvotech Reports Financial Results for First three Months of 2023 and Provides Business Update - Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022
Alvotech announced strong financial results for Q1 2023, with revenues rising to $15.9 million, a substantial increase compared to $0.8 million in Q1 2022. The company is expanding its biosimilar portfolio, which includes five candidates now in development. However, it faces challenges, such as resolving deficiencies noted in a recent FDA inspection before receiving approval for AVT02, a biosimilar to Humira. Alvotech's ongoing efforts and strategic partnerships aim to address these challenges while they prepare for future product launches.
Read more →ALVO▼ -7.3%on this newsshared move
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
Alvotech, a biotech company specializing in biosimilars, will actively participate in the Morgan Stanley Annual Sustainable Finance Summit on May 22, 2023. The event will include a fireside chat and investor meetings, showcasing Alvotech's commitment to sustainability and patient access through lower-cost medicines. Alvotech emphasizes the use of renewable energy in its operations and highlights its dedication to gender equality with annual equal pay certifications. The company continues to expand its biosimilar pipeline and global partnerships.
Read more →ALVOAlvotech Issues Annual Equality Report Covering 2022
Alvotech has published its second annual Equality Report for 2022, highlighting significant strides in gender equality within its workforce. The company has successfully reduced its unexplained gender pay gap to 1.6%, down from 5.2% in 2020, and has implemented an Equality Policy based on Icelandic law globally. The report showcases Alvotech's commitment to fostering diversity, revealing that 53% of new hires in 2022 were women. Alvotech's dedication to talent recruitment and advancement based on merit underscores its focus on sustainability and ethical business practices.
Read more →ALVOAlvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea (aflibercept)
Alvotech has entered an exclusive commercialization agreement with Polifarma for AVT06, a proposed biosimilar to Eylea, in Turkey. Alvotech will handle development and manufacturing while Polifarma is responsible for market registration and commercialization. This collaboration is expected to enhance patient access to affordable treatment for eye diseases in the growing Turkish market. AVT06 is currently undergoing clinical development to evaluate its efficacy and safety compared to Eylea.
Read more →ALVOAlvotech Soci t anonyme Si ge Social: 9, Rue de Bitbourg, L-1273 Luxembourg, Grand-Duch de Luxembourg R.C.S. Luxembourg: B 258.884 (the Company ) CONVENING NOTICE The shareholders of Alvotech are invited to participate a
Alvotech has issued a convening notice for the Annual and Extraordinary General Meeting of Shareholders scheduled for June 6, 2023. The meeting will be held in Luxembourg, and shareholders are invited to participate either in person or through a proxy. Key agenda items and draft resolutions will be made available on the company's website. Shareholders must confirm their participation by a specified deadline and are advised of the requirements to vote during the meeting.
Read more →ALVOAlvotech S.A. Annual General Meeting to be held June 6, 2023
Alvotech S.A. has announced that its Annual General Meeting (AGM) will take place on June 6, 2023, at 09:00 a.m. CEST in Luxembourg. The meeting will be held at the premises of Arendt & Medernach S.A., and details regarding the final agenda are available through an attached document. Shareholders can find all relevant meeting materials and additional information on Alvotech's official website.
Read more →ALVOAlvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria The clinical study will compare AVT05 and Simponi in patients with moderate to severe rheumatoid arthritis REYKJ
Alvotech has announced the launch of a confirmatory clinical study for AVT05, a proposed biosimilar to Simponi and Simponi Aria, targeting adult patients with moderate to severe rheumatoid arthritis. This randomized, double-blind study aims to compare the efficacy, safety, and immunogenicity of AVT05 with that of the reference product, Simponi. The study is a key milestone in Alvotech's biosimilars development pipeline, emphasizing the company's commitment to improving patient access to affordable biologic therapies. AVT05 is still in the investigational stage and has not yet achieved regulatory approval.
Read more →ALVOAlvotech Investigated For Potential Securities Law Violations by Block & Leviton LLP; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Alvotech (NASDAQ: ALVO) is being investigated by Block & Leviton for potential violations of securities laws following a complete response letter issued by the FDA. This letter pertains to the company's Biologics License Application for AVT02, a biosimilar candidate for Humira. As a consequence, Alvotech's stock plummeted by over 20% shortly after the announcement. Block & Leviton encourages investors who suffered losses to reach out for possible recovery options.
Read more →ALVOAlvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
Alvotech (NASDAQ: ALVO) has announced that it will release its financial results for the first quarter of 2023 on May 18. The company will host a conference call for a business update on May 19. Alvotech specializes in developing biosimilar medicines and currently has eight candidates in its pipeline targeting various health conditions.
Read more →ALVOAlvotech: Company Investigated by the Portnoy Law Firm
Alvotech (NASDAQ: ALVO) is under investigation by the Portnoy Law Firm for potential securities fraud associated with misleading statements to investors. The investigation follows an announcement from Alvotech revealing deficiencies in its Reykjavik manufacturing facility, as noted by the FDA after their March 2023 inspection. As a result of this news, Alvotech's stock plummeted by 22.1%. The law firm is offering complimentary case evaluations to affected investors and may file a class action suit.
Read more →ALVOSarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer REYKJAVIK, ICELAND (
Alvotech hf. announced the appointment of Sarah Tanksley to its Board of Directors and Sandra Casaca as Chief Quality Officer. Tanksley is recognized for her strong leadership, while Casaca, who has over 25 years of experience in the quality sector, will enhance Alvotech's focus on quality in biosimilar manufacturing. These changes aim to strengthen the company's capabilities in delivering high-quality biosimilar medicines and support its global operations.
Read more →ALVOAlvotech Provides Regulatory Update on AVT02 Biologics License Application REYKJAVIK, ICELAND (
Alvotech announced the receipt of a complete response letter from the FDA regarding its Biologics License Application for AVT02, a biosimilar candidate for Humira. The letter indicated that certain deficiencies must be resolved before the application can proceed. Alvotech provided comprehensive responses to the FDA's inspection observations and is awaiting feedback. The review for another BLA for AVT02 is ongoing, with a goal date set for June 28, 2023, contingent on the outcome of the facility reinspection.
Read more →ALVOAlvotech Provides Update on Corporate Sustainability Framework
Alvotech, a biotech company focused on biosimilar medicines, has updated its Corporate Sustainability framework and released key ESG indicators for 2022. The company stressed the link between sustainability and long-term success, highlighting its commitment to providing affordable healthcare solutions. With operations powered entirely by renewable energy in Iceland, Alvotech aims to be a leader in the biosimilar industry while ensuring equal pay and gender equality across its global workforce. The creation of a Corporate Sustainability Committee underscores its dedication to ESG matters.
Read more →ALVOAlvotech Announces Increase in Number of Own Shares REYKJAVIK, ICELAND (
Alvotech has announced an increase in its share capital by $140,057.90 through the issuance of 14,005,790 ordinary shares, all subscribed by its subsidiary, Alvotech Manco ehf. This capital raise aims to address the reduction of treasury shares following a recent private placement. The company currently holds eight biosimilar candidates across various therapeutic areas, with a strategy to leverage commercial partnerships for expanding its market presence globally. The total number of issued shares has now increased from 275,721,672 to 289,727,462.
Read more →ALVOAlvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara , at 2023 American Academy of Dermatology (AAD) Annual Meeting
Alvotech announced the presentation of clinical study data for AVT04, its proposed biosimilar to Stelara, at the 2023 American Academy of Dermatology Annual Meeting. Two posters detailing pharmacokinetics and confirmatory clinical studies were presented, showcasing positive outcomes in the evaluation of AVT04's equivalence to the reference product. The company has submitted marketing applications in the U.S. and Europe, furthering its efforts toward gaining regulatory approval for AVT04.
Read more →ALVOAlvotech Reports Financial Results for Full Year 2022 and Provides Business Update Full Year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by bo
Alvotech has reported a remarkable financial performance for the full year 2022, achieving a 114% increase in total revenue to $85.0 million. The company is preparing for an FDA reinspection of its Reykjavik facility, which is crucial for the approval of its biosimilar to Humira, set for review on April 13, 2023. In addition to its revenue surge, Alvotech successfully launched the AVT02 product in multiple markets and secured substantial financing through private placements. However, it also reported a significant net loss of $513.6 million for the year.
Read more →ALVOAlvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
Alvotech (NASDAQ: ALVO) announced the release of its 2022 full year financial results, scheduled for after U.S. markets close on March 1, 2023. Following the financial release, the company will hold a business update conference call on March 2, 2023, at 8:00 am ET. The call will be available via a live audio webcast, with access details provided on Alvotech’s investor website. Alvotech emphasizes its commitment to biosimilars and aims to be a leading global provider.
Read more →ALVOSettlement of Alvotech Private Share Placement Completed REYKJAVIK, ICELAND (
Alvotech has completed a private share placement involving the transfer of 11,834,061 treasury shares. The transaction, initially announced on January 23, 2023, is aimed at bolstering the company's financial position by using the net proceeds for corporate purposes and reducing reliance on external funding sources. Alvotech is focused on the development and manufacture of biosimilar medicines and has an extensive pipeline targeting various health conditions across multiple global markets.
Read more →ALVOEMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara (ustekinumab) Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filin
The European Medicines Agency (EMA) accepted the Marketing Authorization Application for AVT04, Alvotech's proposed biosimilar to Stelara (ustekinumab). This acceptance represents a significant step towards providing a new treatment option for patients with inflammatory conditions in Europe. The companies expect the EMA to recommend approval in the latter half of 2023, potentially enhancing access to affordable biologic therapies. With successful previous studies demonstrating therapeutic equivalence, Alvotech and STADA are optimistic about the product's future in the competitive biosimilar market.
Read more →ALVOTABLE OF CONTENTS 1. General description 3 2. Risk factors 6 3. Summary of main terms of the Bond 10 4. Terms of the Bond 13 4.1 Interpretation 13 4.2 Status 13 4.3 Adherence to Intercreditor Deed and Subordination Agree
Alvotech is preparing to list a Convertible Bond Instrument on Nasdaq First North Growth Market Iceland, aimed at attracting new investors. The bond, originally issued in December 2022, is expected to enhance asset classification and provide better transparency for investors. While the listing may promote diversification, potential risks are associated with investing in a market that has less regulatory oversight than traditional avenues. Its accessibility is primarily limited to qualified investors, and there are restrictions on distribution in certain jurisdictions.
Read more →ALVOAlvotech enters into commercialization agreement with Advanz Pharma for proposed biosimilar to Xolair (omalizumab) - Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair (omalizumab) in the European Ec
Alvotech has signed an exclusive commercialization agreement with Advanz Pharma for AVT23, a proposed biosimilar to Xolair, covering multiple regions including the EU and Canada. Alvotech will focus on the development and manufacturing of AVT23, while Advanz Pharma will manage registration and commercialization efforts. The collaboration highlights a commitment to improving patient access to affordable biologics, with a potential market size exceeding $1 billion. However, it is important to note that AVT23 has not yet received regulatory approval, posing inherent risks.
Read more →ALVOAlvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia AVT02 as Simlandi is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure REYKJAVIK, IC
Alvotech and Bioventure have announced that the Saudi Food & Drug Authority has approved AVT02, a biosimilar to Humira, which will be marketed as Simlandi in Saudi Arabia. This approval marks a significant milestone for the local healthcare system, improving access to an essential treatment for various inflammatory diseases. Alvotech's strategic partnership with Bioventure aims to address the high costs often associated with biologics. The approval and distribution of Simlandi could enhance patient quality of life in the region.
Read more →ALVOAlvotech Completes $137 Million Private Share Placement REYKJAVIK, ICELAND (
Alvotech has finalized a private placement of approximately $137 million, offering its ordinary shares at a price of $11.57 each. This private placement, which commenced on January 19, 2023, was directed solely at professional clients in Iceland in compliance with relevant regulations. The net proceeds from this offering will be used for general corporate purposes, and closing is expected by February 10, 2023. Alvotech is committed to enhancing its capabilities in developing biosimilar medicines for various indications.
Read more →ALVO▼ -5.2%on this newsshared move
Alvotech S.A. Inside information Alvotech initiates proposed private share placement to professional clients and eligible counterparties in Iceland Alvotech (NASDAQ: ALVO), a global biotech company specializing in the de
Alvotech has announced the commencement of a proposed private share placement aimed at professional clients and eligible counterparties in Iceland. The initiative is part of the company's strategy to finance its operations and is compliant with European regulations. However, completion of the placement is uncertain, and it is restricted to particular investor classes. Further details will be released upon completion of the placement.
Read more →ALVO▲ +5%on this news
Alvotech and Fuji Pharma Expand Partnership Adding a New Biosimilar Candidate
Alvotech has expanded its partnership with Fuji Pharma by adding a new biosimilar candidate to their exclusive commercialization agreement in Japan. This follows the recent submission of a marketing approval application for another biosimilar developed under their collaboration. Both companies aim to enhance patient access to essential biologic medicines within the growing Japanese market. This partnership now encompasses seven biosimilars, showcasing Alvotech's commitment to becoming a leader in biosimilars and Fuji's ambition to lead the market in Japan.
Read more →ALVOAlvotech Initiates Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi and Simponi Aria REYKJAVIK, ICELAND (
Alvotech has announced the initiation of a pharmacokinetic study for AVT05, its proposed biosimilar for Simponi and Simponi Aria. This study will evaluate the pharmacokinetics, safety, and tolerability of AVT05 in healthy adult subjects, marking the fifth biosimilar candidate from Alvotech entering clinical studies. The company emphasizes its commitment to providing accessible and affordable biologic treatments as it expands its portfolio, which currently includes eight products targeting various diseases. As the market for the reference product generated over $2.2 billion in revenue, the company's advancement signals a strategic move in the biosimilar field.
Read more →ALVO▲ +6.8%on this news· ran to +20% by day 3shared move
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara (ustekinumab) - The U.S. Food and Drug Administration s (FDA) regulatory review is anticipated to be
Alvotech and Teva Pharmaceuticals announced that the U.S. FDA has accepted their Biologics License Application for AVT04, a proposed biosimilar to Stelara (ustekinumab). The companies anticipate that the FDA's review will be completed in the second half of 2023. Previous studies have shown AVT04 to demonstrate therapeutic equivalence and safety in patients with chronic plaque-type psoriasis. The collaboration aims to enhance access to affordable treatment options for inflammatory conditions.
Read more →ALVO▲ +17.3%on this news
Update on U.S. Regulatory Status of AVT02, Alvotech s Proposed High-Concentration, Interchangeable Biosimilar to Humira U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on
Update on U.S. Regulatory Status of AVT02, Alvotech s Proposed High-Concentration, Interchangeable Biosimilar to Humira REYKJAVIK, ICELAND (December 22, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medici
Read more →ALVOAlvotech Completes $59.7 Million Private Placement
REYKJAVIK, Iceland, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced completion of a private placement of approximately US$59.7 milli
Read more →ALVOCorrection to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated con
Correction to Total Amount in Announcement About Private Placement Published 2022-12-16 09:00 GMT Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds. The aggregate principal amount is approxim
Read more →ALVO▲ +7%on this news
Alvotech Shares Start Trading on Nasdaq Iceland Main Market
Listing on the Main Market can increase visibility, which may allow the company to appear in both domestic and global indexes Alvotech became first dual-listed Icelandic company in the U.S. and Iceland after market debut in June, trading under the symbol “ALVO“ Robert Wessman F
Read more →ALVO▲ +8.7%on this newsshared move
Alvotech and STADA Broaden Access to Hukyndra adalimumab biosimilar in Europe
Hukyndra® (adalimumab) launches in Belgium, Bulgaria, Croatia, Czech Republic, Latvia, Romania, and Slovenia, increasing availability of high-concentration, citrate-free adalimumab in Europe Follows initial introduction of Hukyndra in nine countries: Austria, Estonia, Finland, F
Read more →ALVOAlvotech publishes prospectus related to the admission to trading and listing on Nasdaq Iceland Main Market
Alvotech publishes prospectus related to the admission to trading and listing on Nasdaq Iceland Main Market Reference is made to the announcement issued on December 2, 2022 confirming that Nasdaq Iceland has approved Alvotech S.A s ( Alvotech ) request for admission to trading
Read more →ALVOAlvotech submits its application for admission of the company s shares to trading on Nasdaq Iceland Main Market Alvotech S.A. ( Alvotech ) has submitted its application to Nasdaq Iceland for admission of its shares for t
Alvotech submits its application for admission of the company s shares to trading on Nasdaq Iceland Main Market Alvotech S.A. ( Alvotech ) has submitted its application to Nasdaq Iceland for admission of its shares for trading on the Nasdaq Iceland Main Market under the ticker
Read more →ALVOAlvotech Announces Changes to its Leadership Team
Hafrun Fridriksdottir, previously Executive VP and Head of Global R&D at Teva, will become Chief Operating Officer Mark Levick has decided to step down as Chief Executive Officer and Robert Wessman, Executive Chairman and founder, will become CEO Changes to the leadership team
Read more →ALVOAlvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update Revenue for first nine months of 2022 increased to $59.2 million, compared to $2.0 million for the same period in 2021 Discuss
Alvotech Reports Financial Results for First Nine Months of 2022 And Provides Business Update REYKJAVIK, ICELAND (November 15, 2022) Alvotech (NASDAQ: ALVO, or the Company ), a global biotech company specializing in the development and manufacture of biosimilar medicines for p
Read more →ALVOAlvotech Secures Financing Facilities of Approximately $136 Million - Existing senior bonds upsized by $70 million with additional investment from a consortium of institutional investors - Alvotech acquires the Reykjavik
Alvotech Secures Financing Facilities of Approximately $136 Million REYKJAVIK, ICELAND (November 16, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financing
Read more →ALVO▲ +6.5%on this newsshared move
Alvotech Announces Australian Marketing Authorization for AVT02, a Biosimilar to Humira
Increases availability of cost-effective high-concentration low-volume adalimumab in Australia First approved biosimilar from the partnership with Cipla, which also includes four other biosimilar candidates REYKJAVIK, Iceland and MUMBAI, India, Nov. 14, 2022 (GLOBE NEWSWIRE) --
Read more →ALVO▲ +5.5%on this newsshared move
Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira , at 2022 American College of Rheumatology Conference
Alvotech will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02 The switching study was conducted to investigate the pharmacokinetics, immunogenicity, efficacy and safety in patients undergoing repeated switches between Humira an
Read more →ALVOAlvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022
REYKJAVIK, Iceland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months
Read more →ALVOAlvotech to Participate in Upcoming Jefferies London Healthcare Conference in November REYKJAVIK, ICELAND (
Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November REYKJAVIK, ICELAND (October 26, 2022) Alvotech (NASDAQ: ALVO), a global biotech specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today
Read more →ALVOAlvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care Expanded partnership covers biosimilar candidates in immunol
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care REYKJAVIK, ICELAND & BOUCHERVILLE, QC (October 19, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specializi
Read more →ALVOAlvotech s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan REYKJAVIK, ICELAND (
Alvotech s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan REYKJAVIK, ICELAND (October 17, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients wor
Read more →ALVOAlvotech Appoints Sarah Tanksley as Chief Quality Officer REYKJAVIK ICELAND (
Alvotech Appoints Sarah Tanksley as Chief Quality Officer REYKJAVIK ICELAND (October 11, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley w
Read more →ALVO▼ -14.9%on this news
Alvotech and STADA increase access to adalimumab for patients in Switzerland with the launch of Hukyndra Hukyndra increases availability of high-concentration, low-volume, citrate-free presentations of adalimumab Exclusi
Alvotech and STADA increase access to adalimumab for patients in Switzerland with the launch of Hukyndra REYKJAVIK ICELAND; BAD VILBEL, GERMANY (September 22, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar
Read more →ALVOAlvotech Reports Update on Initial AVT02 Biologics License Application REYKJAVIK ICELAND (
Alvotech Reports Update on Initial AVT02 Biologics License Application REYKJAVIK ICELAND (September 5, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that A
Read more →ALVOAlvotech Reports First Half 2022 Financial Results and Business Update
Secured funding of approximately $185 million in gross proceeds through the merger with OACB (the “Business Combination”) and private placement investment in public equity (PIPE) financing Debuted as publicly-traded company on Nasdaq Stock Exchange in U.S. and on Nasdaq First No
Read more →ALVOAlvotech Unaudited Condensed Consolidated Interim Financial Statements as of 30 June 2022 and for the six months ended 30 June 2022 and 30 June 2021 Table of Contents Table of Contents Unaudited Condensed Consolidated In
Table of Contents Condensed Consolidated Interim Financial Statements as of 30 June 2022 and for the six months ended 30 June 2022 and 30 June 2021 Table of Contents Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss
Read more →ALVOAlvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021 Alvotech releases ESG indicators covering both 2020 and 2021 Carbon neutrality for scope 1 and 2 emissions achieved
Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering REYKJAVIK, ICELAND (August 29, 2022) Alvotech (NASDAQ: ALVO) (the Company ), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients wo
Read more →ALVOAlvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva Alvotech has now entered four biosimilar candidates into confirmatory patient studies Combined sales of Prolia and Xgeva
Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva REYKJAVIK, ICELAND (August 25, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldw
Read more →ALVOAlvotech to Participate in Two Upcoming Investor Conferences in September 2022
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in two upcoming investor conferences in September 2022. Representa
Read more →ALVO▲ +18.5%on this news
Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on
Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022 REYKJAVIK, ICELAND (August 15, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specialized in th
Read more →ALVOAlvotech s Board of Directors Approves Plan to prepare for listing on Nasdaq Main Market in Iceland - After becoming the first Icelandic company to list its shares both in the U.S. and Iceland, Alvotech prepares to move
Alvotech s Board of Directors Approves Plan to prepare for listing on Nasdaq Main Market in Iceland REYKJAVIK, ICELAND (August 12, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldw
Read more →ALVO▲ +5.9%on this news
Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva Prolia and Xgeva (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion
Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva REYKJAVIK, ICELAND (July 20, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,
Read more →ALVO▲ +14.3%on this news· ran to +33% by day 3shared move
Published: 2022-07-15 10:00:00 CEST Alvotech S.A. Interim information Filing of Preliminary Prospectus on Form F-1 with U.S. Securities and Exchange Commission On 14 July 2022, Alvotech filed a Registration Statement on
Published: 2022-07-15 10:00:00 CEST Filing of Preliminary Prospectus on Form F-1 with U.S. Securities and Exchange Commission On 14 July 2022, Alvotech filed a Registration Statement on Form F-1 (the Preliminary Prospectus ) with the U.S. Securities and Exchange Commission (th
Read more →ALVOAlvotech Soci t anonyme Registered office: 9, rue de Bitbourg, L-1273 Luxembourg R.C.S. Luxembourg: B258884 Aztiq and Alvogen subscribe to shares in Alvotech at listing price of $10 per share Alvogen Lux Holdings S. r.l.
Registered office: 9, rue de Bitbourg, L-1273 Luxembourg R.C.S. Luxembourg: B258884 subscribe to shares in Alvotech at listing price of $10 per share Alvogen Lux Holdings S. r.l. ( Alvogen ) and Aztiq Pharma Partners S. r.l. ( Aztiq ) have each subscribed to 2,500,000 newly i
Read more →ALVOAlvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company
Four new members enhance independence and diversity of Board of Directors Alvotech is dual listed on NASDAQ in the U.S. and NASDAQ First North Growth Market in Iceland under the symbol “ALVO” REYKJAVIK, Iceland, July 14, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a globa
Read more →ALVO▼ -15.8%on this news
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studies Eylea (aflibercept) is used for the treatment of eye dis
Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea REYKJAVIK, ICELAND (July 7, 2022) Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the i
Read more →ALVO▼ -8.5%on this newsshared move
Alvotech Soci t anonyme Registered office: 9, rue de Bitbourg, L-1273 Luxembourg R.C.S. Luxembourg: B258884 Increase of share capital and creation of treasury share pool to meet obligations with respect to Warrants issue
Registered office: 9, rue de Bitbourg, L-1273 Luxembourg R.C.S. Luxembourg: B258884 Increase of share capital and creation of treasury share pool to meet obligations with respect to Warrants issued by Alvotech, the Alvotech Management Incentive Plan, as well as Alvotech s opti
Read more →ALVOAlvotech Debuts on NASDAQ First North Growth Market Becoming First Dual-Listed Icelandic Company in United States and Iceland After the largest debut by an Icelandic company on a U.S. stock exchange, Alvotech is set to l
Alvotech Debuts on NASDAQ First North Growth Market Becoming First Dual-Listed Icelandic Company in United States and Iceland REYKJAVIK, ICELAND (June 22, 2022) Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for pat
Read more →ALVOAlvotech Company Description, June 2022 Listing of shares on Nasdaq First North Iceland Table of Contents This Company Description 1 (hereafter referred to as Company Description ) has been prepared by Alvotech, a public
Table of Contents Alvotech Company Description, June 2022 Listing of shares on Nasdaq First North Iceland Table of Contents This Company Description1 (hereafter referred to as Company Description ) has been prepared by Alvotech, a public limited liability company (soci t anon
Read more →ALVOAlvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16 - Debut on Nasdaq follows completion of the company s business combination with Oaktree Acquisition Corp. II, which inc
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16 REYKJAVIK, ICELAND & NEW YORK (June 15, 2022) Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide
Read more →ALVOSupplement dated 22 June 2022 to the Company Description dated 21 June 2022 (incorporated in Luxembourg as a limited liability company) This supplement (the Supplement ) to the Company Description, dated 21 June 2022 (to
Table of Contents Supplement dated 22 June 2022 to the Company Description dated (incorporated in Luxembourg as a limited liability company) This supplement (the Supplement ) to the Company Description, dated 21 June 2022 (together Company Description ), has been prepared by
Read more →Competitive Position
How ALVO ranks across every disease it competes inCompetitive Position is a premium feature
See how ALVO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial